
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.cc84172e9e16.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.b634933a977d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.913c7dcab8ff.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.a2ef7ca69e4b20dff539.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs2.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-journal.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.3c5d12ff2e4beea20136.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="939BE807DB0F4BC50000575CE4365202.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="0.0" />

<meta name="ncbi_domain" content="brjcancer" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC2377106/" />


    


    <script>
        
            var ncbiBaseUrl = "https://www.ncbi.nlm.nih.gov";
        
        var useOfficialGovtHeader = true;
    </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377106/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="British Journal of Cancer" /><meta name="citation_title" content="A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs" /><meta name="citation_author" content="R A Spooner" /><meta name="citation_author_institution" content="Cancer Research UK Centre for Cancer Therapeutics at the Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK" /><meta name="citation_author_institution" content="Cancer Research UK Centre for Cell and Molecular Biology at the Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK" /><meta name="citation_author" content="F Friedlos" /><meta name="citation_author_institution" content="Cancer Research UK Centre for Cancer Therapeutics at the Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK" /><meta name="citation_author" content="K Maycroft" /><meta name="citation_author_institution" content="Cancer Research UK Centre for Cell and Molecular Biology at the Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK" /><meta name="citation_author" content="S M Stribbling" /><meta name="citation_author_institution" content="Cancer Research UK Centre for Cancer Therapeutics at the Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK" /><meta name="citation_author" content="J Roussel" /><meta name="citation_author_institution" content="Novartis Pharmaceutical AG, Pharmaceutical Research, CH-4002, Basel, Switzerland" /><meta name="citation_author" content="J Brueggen" /><meta name="citation_author_institution" content="Novartis Pharmaceutical AG, Pharmaceutical Research, CH-4002, Basel, Switzerland" /><meta name="citation_author" content="B Stolz" /><meta name="citation_author_institution" content="Novartis Pharmaceutical AG, Pharmaceutical Research, CH-4002, Basel, Switzerland" /><meta name="citation_author" content="T O'Reilly" /><meta name="citation_author_institution" content="Novartis Pharmaceutical AG, Pharmaceutical Research, CH-4002, Basel, Switzerland" /><meta name="citation_author" content="J Wood" /><meta name="citation_author_institution" content="Novartis Pharmaceutical AG, Pharmaceutical Research, CH-4002, Basel, Switzerland" /><meta name="citation_author" content="A Matter" /><meta name="citation_author_institution" content="Novartis Pharmaceutical AG, Pharmaceutical Research, CH-4002, Basel, Switzerland" /><meta name="citation_author" content="R Marais" /><meta name="citation_author_institution" content="Cancer Research UK Centre for Cell and Molecular Biology at the Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK" /><meta name="citation_author" content="C J Springer" /><meta name="citation_author_institution" content="Cancer Research UK Centre for Cancer Therapeutics at the Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK" /><meta name="citation_publication_date" content="2003/05/05" /><meta name="citation_issue" content="10" /><meta name="citation_volume" content="88" /><meta name="citation_firstpage" content="1622" /><meta name="citation_doi" content="10.1038/sj.bjc.6600911" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC2377106/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC2377106/" /><meta name="citation_pmid" content="12771932" /><meta name="DC.Title" content="A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Nature Publishing Group" /><meta name="DC.Contributor" content="R A Spooner" /><meta name="DC.Contributor" content="F Friedlos" /><meta name="DC.Contributor" content="K Maycroft" /><meta name="DC.Contributor" content="S M Stribbling" /><meta name="DC.Contributor" content="J Roussel" /><meta name="DC.Contributor" content="J Brueggen" /><meta name="DC.Contributor" content="B Stolz" /><meta name="DC.Contributor" content="T O'Reilly" /><meta name="DC.Contributor" content="J Wood" /><meta name="DC.Contributor" content="A Matter" /><meta name="DC.Contributor" content="R Marais" /><meta name="DC.Contributor" content="C J Springer" /><meta name="DC.Date" content="2003 May 19" /><meta name="DC.Identifier" content="10.1038/sj.bjc.6600911" /><meta name="DC.Language" content="en" /><meta property="og:title" content="A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs" /><meta property="og:type" content="article" /><meta property="og:description" content="We have generated fusion proteins between vascular endothelial growth factor (VEGF) and the bacterial enzyme carboxypeptidase G2 (CPG2) that can activate the prodrug 4-&#x0005b;(2-chloroethyl)(2-mesyloxyethyl)amino&#x0005d;benzoyl--glutamic acid (CMDA). ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377106/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" />


</head>
<body >

   
    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    


    
        

<section class="pmc-alerts">
    
    <div role="alert" class="pmc-alert pmc-alert--info" role="region" aria-label="Alert" aria-hidden="false"  data-key="pmc-alert-welcome">
        <div class="pmc-alert__body pmc-alert--ncbi-icon">
            <div class="pmc-alert__content">
                <p>
                    <strong>
                        Preview improvements coming to the PMC website in October 2024.
                        <a href="https://ncbiinsights.ncbi.nlm.nih.gov/2024/03/14/preview-pmc-improvements/" data-ga-category="cloud_beta_banner" data-ga-label="learn_more" data-ga-action="on_pmc2020">Learn More</a> or
                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2377106/" data-ga-category="cloud_beta_banner" data-ga-action="on_pmc2020" data-ga-label="go_to_cloud">Try it out now</a>.
                    </strong>
                </p>
            </div>
        </div>
    </div>
    
</section>
    

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/334/">Br J Cancer</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/166068/">v.88(10); 2003 May 19</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC2377106
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC2377106/pdf/88-6600911a.pdf" class="int-view">PDF (228K)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/2377106/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/2377106/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="2377106" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2377106%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="7A2ddqVUMIutpJIxyALq6OpoporpG0hUQuMLI4SWreQszJ50BBDwvdKgIpx2MASP">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2377106%2F&amp;text=A%20novel%20vascular%20endothelial%20growth%20factor-directed%20therapy%20that%20selectively%20activates%20cytotoxic%20prodrugs" alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2377106%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377106/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC2377106/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/12771932/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC2377106/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/12771932/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC2377106/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/2377106/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/334/">Br J Cancer</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/166068/">v.88(10); 2003 May 19</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC2377106
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-brjcancer.gif" alt="Logo of brjcancer" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area target="pmc_ext" rel="noopener noreferrer" shape="rect" coords="185,2,260,20" alt="BJC Homepage" title="BJC Homepage" href="http://www.nature.com/bjc/index.html" ref="reftype=publisher&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /><area target="pmc_ext" rel="noopener noreferrer" shape="rect" coords="261,2,301,20" alt="BJC Advance online publication" title="BJC Advance online publication" href="http://www.nature.com/bjc/journal/vaop/ncurrent/index.html" ref="reftype=publisher&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /><area target="pmc_ext" rel="noopener noreferrer" shape="rect" coords="304,2,400,20" alt="BJC Current Issue" title="BJC Current Issue" href="http://www.nature.com/bjc/current/" ref="reftype=publisher&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /><area target="pmc_ext" rel="noopener noreferrer" shape="rect" coords="402,2,498,20" alt="Submitting an article to BJC" title="Submitting an article to BJC" href="http://www.nature.com/bjc/authors/submit.html" ref="reftype=publisher&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /><area target="pmc_ext" rel="noopener noreferrer" shape="rect" coords="406,52,498,73" alt="Web feeds" title="Web feeds" href="http://www.nature.com/bjc/about/web_feeds.html" ref="reftype=publisher&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div class="citation-default"><div class="part1"><span id="pmcmata">Br J Cancer.</span> 2003 May 19; 88(10): 1622–1630. </div><div class="part2"><span class="fm-vol-iss-date">Published online 2003 May 13. </span>  <span class="doi"><span>doi: </span><a href="//doi.org/10.1038%2Fsj.bjc.6600911" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1038/sj.bjc.6600911</a></span></div></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC2377106</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/12771932">12771932</a></div></div></div><h1 class="content-title">A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Spooner%20RA%5BAuthor%5D" class="affpopup" co-rid="_co_idm139987918777088" co-class="co-affbox">R A Spooner</a>,<sup>1,</sup><sup>2</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Friedlos%20F%5BAuthor%5D" class="affpopup" co-rid="_co_idm139987925443152" co-class="co-affbox">F Friedlos</a>,<sup>1</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Maycroft%20K%5BAuthor%5D" class="affpopup" co-rid="_co_idm139987928435312" co-class="co-affbox">K Maycroft</a>,<sup>2</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Stribbling%20SM%5BAuthor%5D" class="affpopup" co-rid="_co_idm139987928433328" co-class="co-affbox">S M Stribbling</a>,<sup>1</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Roussel%20J%5BAuthor%5D" class="affpopup" co-rid="_co_idm139987925098032" co-class="co-affbox">J Roussel</a>,<sup>3</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Brueggen%20J%5BAuthor%5D" class="affpopup" co-rid="_co_idm139987925096048" co-class="co-affbox">J Brueggen</a>,<sup>3</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Stolz%20B%5BAuthor%5D" class="affpopup" co-rid="_co_idm139987925094064" co-class="co-affbox">B Stolz</a>,<sup>3</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=O%27Reilly%20T%5BAuthor%5D" class="affpopup" co-rid="_co_idm139987930658672" co-class="co-affbox">T O'Reilly</a>,<sup>3</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Wood%20J%5BAuthor%5D" class="affpopup" co-rid="_co_idm139987930656688" co-class="co-affbox">J Wood</a>,<sup>3</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Matter%20A%5BAuthor%5D" class="affpopup" co-rid="_co_idm139987967510080" co-class="co-affbox">A Matter</a>,<sup>3</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Marais%20R%5BAuthor%5D" class="affpopup" co-rid="_co_idm139987967508096" co-class="co-affbox">R Marais</a>,<sup>2</sup> and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Springer%20CJ%5BAuthor%5D" class="affpopup" co-rid="_co_idm139987967506112" co-class="co-affbox">C J Springer</a><sup>1,</sup><sup>*</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm139987918777088"><h3 class="no_margin">R A Spooner</h3><p><sup>1</sup>Cancer Research UK Centre for Cancer Therapeutics at the Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK</p><p><sup>2</sup>Cancer Research UK Centre for Cell and Molecular Biology at the Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Spooner%20RA%5BAuthor%5D">R A Spooner</a></div></div><div id="_co_idm139987925443152"><h3 class="no_margin">F Friedlos</h3><p><sup>1</sup>Cancer Research UK Centre for Cancer Therapeutics at the Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Friedlos%20F%5BAuthor%5D">F Friedlos</a></div></div><div id="_co_idm139987928435312"><h3 class="no_margin">K Maycroft</h3><p><sup>2</sup>Cancer Research UK Centre for Cell and Molecular Biology at the Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Maycroft%20K%5BAuthor%5D">K Maycroft</a></div></div><div id="_co_idm139987928433328"><h3 class="no_margin">S M Stribbling</h3><p><sup>1</sup>Cancer Research UK Centre for Cancer Therapeutics at the Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Stribbling%20SM%5BAuthor%5D">S M Stribbling</a></div></div><div id="_co_idm139987925098032"><h3 class="no_margin">J Roussel</h3><p><sup>3</sup>Novartis Pharmaceutical AG, Pharmaceutical Research, CH-4002, Basel, Switzerland</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Roussel%20J%5BAuthor%5D">J Roussel</a></div></div><div id="_co_idm139987925096048"><h3 class="no_margin">J Brueggen</h3><p><sup>3</sup>Novartis Pharmaceutical AG, Pharmaceutical Research, CH-4002, Basel, Switzerland</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Brueggen%20J%5BAuthor%5D">J Brueggen</a></div></div><div id="_co_idm139987925094064"><h3 class="no_margin">B Stolz</h3><p><sup>3</sup>Novartis Pharmaceutical AG, Pharmaceutical Research, CH-4002, Basel, Switzerland</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Stolz%20B%5BAuthor%5D">B Stolz</a></div></div><div id="_co_idm139987930658672"><h3 class="no_margin">T O'Reilly</h3><p><sup>3</sup>Novartis Pharmaceutical AG, Pharmaceutical Research, CH-4002, Basel, Switzerland</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=O%27Reilly%20T%5BAuthor%5D">T O'Reilly</a></div></div><div id="_co_idm139987930656688"><h3 class="no_margin">J Wood</h3><p><sup>3</sup>Novartis Pharmaceutical AG, Pharmaceutical Research, CH-4002, Basel, Switzerland</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Wood%20J%5BAuthor%5D">J Wood</a></div></div><div id="_co_idm139987967510080"><h3 class="no_margin">A Matter</h3><p><sup>3</sup>Novartis Pharmaceutical AG, Pharmaceutical Research, CH-4002, Basel, Switzerland</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Matter%20A%5BAuthor%5D">A Matter</a></div></div><div id="_co_idm139987967508096"><h3 class="no_margin">R Marais</h3><p><sup>2</sup>Cancer Research UK Centre for Cell and Molecular Biology at the Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Marais%20R%5BAuthor%5D">R Marais</a></div></div><div id="_co_idm139987967506112"><h3 class="no_margin">C J Springer</h3><p><sup>1</sup>Cancer Research UK Centre for Cancer Therapeutics at the Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Springer%20CJ%5BAuthor%5D">C J Springer</a></div></div></div></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm139987917818320_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139987917818320_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm139987917818320_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm139987917818320_ai" style="display:none"><div class="fm-affl" id="aff1"><sup>1</sup>Cancer Research UK Centre for Cancer Therapeutics at the Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK</div><div class="fm-affl" id="aff2"><sup>2</sup>Cancer Research UK Centre for Cell and Molecular Biology at the Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK</div><div class="fm-affl" id="aff3"><sup>3</sup>Novartis Pharmaceutical AG, Pharmaceutical Research, CH-4002, Basel, Switzerland</div><div id="caf1"><sup>*</sup>Cancer Research UK Centre for Cancer Therapeutics at the Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK. E-mail: <a href="mailto:dev@null" data-email="ku.ca.rci@enilorac" class="oemail">ku.ca.rci@enilorac</a></div></div><div class="fm-article-notes hide half_rhythm" id="idm139987917818320_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2002 Dec 2; Revised 2003 Feb 12; Accepted 2003 Feb 25.</div></div><div class="permissions half_rhythm hide" id="idm139987917818320_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a>  &#x000a9; 2003 Cancer Research UK</div><div class="license half_rhythm">This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <a href="https://creativecommons.org/licenses/by/4.0/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">https://creativecommons.org/licenses/by/4.0/</a>.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm hidden" role="complementary" aria-label="Related or updated information about this article."></div></div><div class="sec"></div><div id="abstract-a.s.b.p" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="abstract-a.s.b.ptitle" style="text-transform: uppercase;">Abstract</h2><!--article-meta--><div><p class="p p-first-last">We have generated fusion proteins between vascular endothelial growth factor (VEGF) and the bacterial enzyme carboxypeptidase G2 (CPG2) that can activate the prodrug 4-&#x0005b;(2-chloroethyl)(2-mesyloxyethyl)amino&#x0005d;benzoyl-<span class="small-caps">L</span>-glutamic acid (CMDA). Three asparagine residues of CPG2 were mutated to glutamine (CPG2(Q)3) to prevent glycosylation during secretion, and truncations of VEGF<sub>165</sub> were fused to either the C- or N-terminal of CPG2. The <em>K</em><sub>m</sub> of the fusion proteins (37.5&#x02009;<em>&#x003bc;</em><span class="small-caps">M</span>) was similar to that of secreted CPG2(Q)3 (29.5&#x02009;<em>&#x003bc;</em><span class="small-caps">M</span>) but greater than that of wild-type CPG2 (8&#x02009;<em>&#x003bc;</em><span class="small-caps">M</span>). The affinity of the fusion proteins for VEGF receptor-2 (VEGFR2) (<em>K</em><sub>d</sub>&#x0003d;0.5&#x02013;1.1&#x02009;n<span class="small-caps">M</span>) was similar to that of &#x0005b;<sup>125</sup>I&#x0005d;VEGF (<em>K</em><sub>d</sub>&#x0003d;0.5&#x02009;n<span class="small-caps">M</span>) (ELISA) or slightly higher (<em>K</em><sub>d</sub>&#x0003d;1.3&#x02013;9.6&#x02009;n<span class="small-caps">M</span>) (competitive RIA). One protein, VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub>, possessed 140&#x00025; of the enzymic activity of secreted CPG2(Q)3, and had a faster half-maximal binding time for VEGFR2 (77&#x02009;s), than the other candidates (330&#x02009;s). <em>In vitro</em>, VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub> targeted CMDA cytotoxicity only towards VEGFR-expressing cells. The plasma half-life of VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub>
<em>in vivo</em> was 3&#x02009;h, comparable to equivalent values observed in ADEPT. We conclude that enzyme prodrug therapy using VEGF as a targeting moiety represents a promising novel antitumour therapy, with VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub> being a lead candidate.</p></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">CPG2, VEGF, fusion proteins, targeting</span></div></div><div id="body-a.t" class="tsec sec"><h2 class="headless nomenu"></h2><p class="p p-first">Neoangiogenesis is critical for the growth, malignant progression, and metastatic spread of solid tumours and is effected by the release of angiogenic factors that are secreted by tumour cells (<a href="#bib12" rid="bib12" class=" bibr popnode">Fidler and Ellis, 1994</a>; <a href="#bib13" rid="bib13" class=" bibr popnode">Folkman, 1995</a>; <a href="#bib16" rid="bib16" class=" bibr popnode">Fukumura <em>et al</em>, 1998</a>). One such angiogenic factor is vascular endothelial growth factor (VEGF) (<a href="#bib44" rid="bib44" class=" bibr popnode">Tischer <em>et al</em>, 1989</a>). VEGF homodimers act by binding to two cell surface receptors (VEGFRs), known variously as VEGFR-1, <em>flt-1</em>, or fms-like tyrosine kinase, and VEGFR2, KDR, kinase insert domain-containing receptor, or <em>flk-1</em>. Alternate splicing of the VEGF transcript results in the expression of five isoforms of VEGF, comprising molecules consisting of 208, 189, 165, 145, or 121 amino acids (<a href="#bib25" rid="bib25" class=" bibr popnode">Leung <em>et al</em>, 1989</a>; <a href="#bib44" rid="bib44" class=" bibr popnode">Tischer <em>et al</em>, 1989</a>; <a href="#bib20" rid="bib20" class=" bibr popnode">Houck <em>et al</em>, 1991</a>; <a href="#bib32" rid="bib32" class=" bibr popnode">Poltorak <em>et al</em>, 1997</a>). Of these, only the three smallest variants, VEGF<sub>165</sub>, VEGF<sub>145</sub>, and VEGF<sub>121</sub>, are secreted as soluble factors. Cell-surface-associated heparin-like molecules enhance the binding of VEGF to its receptors. Of the three soluble variants, VEGF<sub>165</sub> and VEGF<sub>145</sub> contain such heparin-binding domains whereas VEGF<sub>121</sub> does not.</p><p>VEGFRs are highly expressed in areas of neoangiogenesis, such as in the endothelial cells of tumour vasculature, a restricted distribution that may be exploited to provide targeted therapy, using VEGF as a delivery molecule. Fusion proteins between VEGF and diphtheria toxin are indeed toxic to endothelial cells and to Kaposi's sarcoma cell lines, and inhibit angiogenesis, in a VEGFR-dependent manner (<a href="#bib1" rid="bib1" class=" bibr popnode">Arora <em>et al</em>, 1999</a>). However, the disadvantage of such systems is that each protein molecule can affect only one cell. An alternative to diphtheria toxin is the use of an enzyme that can convert large numbers of molecules of a low molecular weight noncytotoxic prodrug to a cytotoxic drug. We have tested whether the bacterial enzyme carboxypeptidase G2 (CPG2, glutamate carboxypeptidase, E.C.3.4.17.11) can be fused to VEGF, to deliver a prodrug-activating enzyme to proliferating endothelial cells.</p><p>CPG2 hydrolyses several aromatic N-substituted glutamates to release benzoic acid, phenol, and aniline mustards (<a href="#bib39" rid="bib39" class=" bibr popnode">Springer, 1993</a>; <a href="#bib40" rid="bib40" class=" bibr popnode">Springer <em>et al</em>, 1995</a>); or when employing a self-immolative mechanism, can release other conventional therapeutic agents, such as anthracycline antibiotics (<a href="#bib31" rid="bib31" class=" bibr popnode">Niculescu-Duvaz <em>et al</em>, 1999</a>). In this study, we used the noncytotoxic prodrug CMDA that releases <span class="small-caps">L</span>-glutamic acid and benzoic acid nitrogen mustard, a potent DNA-alkylating agent (<a href="/pmc/articles/PMC2377106/figure/fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig1" rid-ob="ob-fig1" co-legend-rid="lgnd_fig1"><span>Figure 1</span></a>). An advantage of alkylating agents is that they are cytotoxic to both cycling and noncycling cells (<a href="#bib15" rid="bib15" class=" bibr popnode">Frei <em>et al</em>, 1988</a>; <a href="#bib43" rid="bib43" class=" bibr popnode">Teicher and Frei, 1988</a>), such as would be found in tumours. CPG2 has previously been used in antibody-directed enzyme-prodrug therapy (ADEPT) in which it is targeted to tumours with tumour-specific antibodies (<a href="#bib2" rid="bib2" class=" bibr popnode">Bagshawe, 1990</a>), an approach in clinical trial (<a href="#bib3" rid="bib3" class=" bibr popnode">Bagshawe <em>et al</em>, 1991</a>; <a href="#bib30" rid="bib30" class=" bibr popnode">Napier <em>et al</em>, 2000</a>). Similarly, expression of CPG2 tethered to the cell surface in gene-directed enzyme-prodrug therapy (GDEPT) leads to extracellular prodrug activation (<a href="#bib27" rid="bib27" class=" bibr popnode">Marais <em>et al</em>, 1997</a>), which in preclinical studies has been shown to generate a bystander effect, where neighbouring cells that do not express CPG2 are also killed (<a href="#bib41" rid="bib41" class=" bibr popnode">Stribbling <em>et al</em>, 2000</a>). By analogy with ADEPT and GDEPT, VEGF-directed delivery of CPG2 will activate CMDA external to the cells and should also lead to killing of both target and bystander cells. The targeting of CPG2 to a tumour using VEGF will also cause destruction of the tumour vasculature and thus lead to significant levels of collateral damage with consequent ischaemic death of the tumour.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="fig1" co-legend-rid="lgnd_fig1"><a href="/pmc/articles/PMC2377106/figure/fig1/" target="figure" rid-figpopup="fig1" rid-ob="ob-fig1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139987927030096"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2377106_88-6600911f1.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 88-6600911f1.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2377106/bin/88-6600911f1.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139987927030096"><a target="object" rel="noopener" href="/pmc/articles/PMC2377106/figure/fig1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig1"><div><a class="figpopup" href="/pmc/articles/PMC2377106/figure/fig1/" target="figure" rid-figpopup="fig1" rid-ob="ob-fig1">Figure 1</a></div><!--caption a7--><div class="caption"><p>Activation of CMDA by CPG2. CPG2 cleaves the benzoic acid mustard prodrug 4-(&#x0005b;2-chloroethyl&#x0005d;&#x0005b;2-mesyloxyethyl&#x0005d;amino)benzoyl-<span class="small-caps">L</span>-glutamic acid (CMDA) to release <span class="small-caps">L</span>-glutamic acid and the mustard drug 4-(&#x0005b;2-chloroethyl&#x0005d;&#x0005b;2-mesoxyethyl&#x0005d;amino)benzoic acid, a potent DNA-alkylating agent.</p></div></div></div><p class="p">In this paper, we describe the construction, expression, and characterisation of a number of fusion proteins between VEGF and CPG2 that can bind to recombinant VEGFR2, and can differentiate between human umbilical vein endothelial cells (HU-V-EC) that express VEGFR2 and human ovarian adenocarcinoma cells (SK-OV-3) that do not. Once bound, these proteins can convert CMDA to its toxic drug derivative and thereby kill the targeted cells. Further, we identify one construct, VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub>, with a combination of features that recommend it as a lead molecule for this targeted therapy, which we call Ligand-Directed Enzyme Prodrug Therapy or LiDEPT.</p></div><div id="sec-a.t.e" class="tsec sec"><h2 class="head no_bottom_margin" id="sec-a.t.etitle" style="text-transform: uppercase;">MATERIALS AND METHODS</h2><div id="sec-a.t.e.b" class="sec sec-first"><p></p><h3 id="sec-a.t.e.btitle" class="inline">Construction of plasmids encoding fusion proteins </h3><p class="p p-first-last">All fusion genes were generated by PCR (<a href="#bib18" rid="bib18" class=" bibr popnode">Ho <em>et al</em>., 1989</a>) and their sequences verified by automated DNA sequencing. For mammalian expression, constructs were cloned into the vector pEFPlink.2, which uses the elongation factor 1<em>&#x003b1;</em> (EF1<em>&#x003b1;</em>) promoter to direct expression in mammalian cells (19). For stable expression, the vector pMCEF&#x02212; was used, which also uses the EF1<em>&#x003b1;</em> promoter to direct expression, but additionally incorporates a neo<sup>R</sup> gene for clone selection (<a href="#bib27" rid="bib27" class=" bibr popnode">Marais <em>et al</em>, 1997</a>).</p></div><div id="sec-a.t.e.c" class="sec"><p></p><h3 id="sec-a.t.e.ctitle" class="inline">Expression and purification of fusion proteins </h3><p class="p p-first-last">Mammalian cells were transfected with expression plasmids using LipofectAmine, as previously described (<a href="#bib27" rid="bib27" class=" bibr popnode">Marais <em>et al</em>., 1997</a>). Expression in insect cell vectors was achieved using the BaculoGold system (Pharmingen) as previously described (<a href="#bib27" rid="bib27" class=" bibr popnode">Marais <em>et al</em>, 1997</a>). For small-scale protein extraction, detergent-soluble extracts were prepared as previously described (<a href="#bib26" rid="bib26" class=" bibr popnode">Marais <em>et al</em>, 1996</a>), except that <em>&#x003b2;</em>-mercaptoethanol was omitted from all the buffers. For bulk protein production, 10<sup>8</sup> Sf9 insect cells were infected with fusion protein-encoding virus in a total of 100&#x02009;ml growth medium. The cells were grown in suspension for up to 9 days. Samples of growth medium (100&#x02009;<em>&#x003bc;</em>l) were monitored daily for CPG2 enzyme activity. When maximum yield was reached, the conditioned growth medium was filtered (0.2&#x02009;<em>&#x003bc;</em>m) and dialysed against 3 &#x000d7; 5l 50&#x02009;m<span class="small-caps">M</span> Tris-HCl pH 8, 500&#x02009;m<span class="small-caps">M</span> NaCl (column loading buffer), and H<sub>6</sub>-tagged proteins were purified by nickel-agarose chromatography, using standard protocols. The proteins were eluted with loading buffer containing 90&#x02009;m<span class="small-caps">M</span> imidazole, and dialysed extensively against 100&#x02009;m<span class="small-caps">M</span> Tris-HCl pH 7.3, 260&#x02009;<em>&#x003bc;</em><span class="small-caps">M</span> ZnCl<sub>2</sub>. The sample was adjusted to 10&#x00025; final glycerol and stored at &#x02212;70&#x000b0;C. CPG2 enzyme assays were performed using a standard assay. Briefly, samples containing CPG2 (100&#x02009;<em>&#x003bc;</em>l) were incubated in 900&#x02009;<em>&#x003bc;</em>l 100&#x02009;m<span class="small-caps">M</span> Tris-HCl pH 7.3, 260&#x02009;<em>&#x003bc;</em><span class="small-caps">M</span> ZnCl<sub>2</sub> containing methotrexate (MTX, 55&#x02009;<em>&#x003bc;</em><span class="small-caps">M</span>), and activity was determined from the rate at which the absorbance at 320&#x02009;nm declined. Immunoprecipitations were performed using standard approaches, using either a CPG2 polyclonal antibody (<a href="#bib19" rid="bib19" class=" bibr popnode">Hogg <em>et al</em>, 1987</a>) or the 9E10 monoclonal antibody, which binds to the myc-epitope tag (<a href="#bib11" rid="bib11" class=" bibr popnode">Evan <em>et al</em>, 1985</a>).</p></div><div id="sec-a.t.e.d" class="sec"><p></p><h3 id="sec-a.t.e.dtitle" class="inline">Receptor binding studies and affinity measurements </h3><p class="p p-first">The apparent affinities of the fusion proteins for VEGFR2 were estimated by adapting a method of solid-phase immunoassay (<a href="#bib19" rid="bib19" class=" bibr popnode">Hogg <em>et al</em>, 1987</a>). To measure the affinity of VEGF for the ligand-binding domain of VEGFR2, the binding to a construct in which the kinase domain was deleted (VEGFR2(&#x00394;KD)m) was determined. Microtitre plates (96 well) were precoated with the 9E10 antibody (20&#x02009;<em>&#x003bc;</em>g&#x02009;ml<sup>&#x02212;1</sup>) and nonspecific sites were blocked with 3&#x00025; skimmed milk powder in phosphate buffered saline (PBS) pH 7.4 containing 0.1&#x00025; Tween-20 (PBS-T). Detergent extracts containing VEGFR2(&#x00394;KD)m were incubated overnight (4&#x000b0;C) and the samples were incubated with &#x0005b;<sup>125</sup>I&#x0005d;VEGF (Amersham Biosciences, UK), followed by three washes with PBS-T and the amount of VEGF bound was determined by scintillation counting. The binding of the fusion proteins to VEGFR2(&#x00394;KD)m was determined as above, but using an ELISA format. Following binding of VEGFR2(&#x00394;KD)m to the antibody-coated microtitre plates, the samples containing the various fusion proteins were incubated with the complexes and the amount of fusion protein bound was measured by ELISA using a rabbit antiserum to CPG2 followed by anti-rabbit horseradish peroxidase and developed using the tetramethylbenzidine liquid substrate system (Sigma-Aldrich, UK).</p><p class="p p-last">Binding affinities were also estimated using a competitive displacement radiolabel receptor assay as previously described (<a href="#bib21" rid="bib21" class=" bibr popnode">Keyt <em>et al</em>, 1996</a>) but substituting VEGFR2(&#x00394;KD)m for the KDR-IgG fusion protein, and using the fusion proteins secreted from insect cells. The apparent dissociation constant (<em>K</em><sub>d</sub>) for each fusion protein was estimated from the concentration required for 50&#x00025; inhibition of binding of &#x0005b;<sup>125</sup>I&#x0005d;VEGF to immobilised VEGFR2(&#x00394;KD)m.</p></div><div id="sec-a.t.e.e" class="sec"><p></p><h3 id="sec-a.t.e.etitle" class="inline">Synthesis of CMDA </h3><p class="p p-first-last">CMDA prodrug was synthesised as described previously (<a href="#bib39" rid="bib39" class=" bibr popnode">Springer, 1993</a>). It was prepared as a 100&#x02009;m<span class="small-caps">M</span> solution in DMSO immediately prior to use.</p></div><div id="sec-a.t.e.f" class="sec"><p></p><h3 id="sec-a.t.e.ftitle" class="inline">Cytotoxicity studies </h3><p class="p p-first">Human umbilical vein endothelial cells (HU-V-EC) were obtained from the American Tissue Culture Collection (ATCC) and were maintained in CS-C medium (Sigma-Aldrich, Missouri, USA), supplemented with 10&#x00025; fetal calf serum and endothelial cell growth factor (Sigma-Aldrich, UK) according to the manufacturer's recommendations. Human ovarian adenocarcinoma SK-OV-3 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10&#x00025; fetal calf serum.</p><p>To determine their inherent sensitivity to CMDA, HU-V-EC and SK-OV-3 cells were seeded (3 &#x000d7; 10<sup>5</sup>&#x02009;cells&#x02009;well<sup>&#x02212;1</sup>) in six-well tissue culture plates. After 2-day growth, the cells were incubated for 19&#x02009;h with 8000, 4000, 2000, 1000, 500, 250, or 125&#x02009;<em>&#x003bc;</em><span class="small-caps">M</span> CMDA that had been diluted in appropriate growth medium. A proportion of the cells (approximately 30&#x00025; for HU-V-EC or approximately 3&#x00025; for SK-OV-3) were replated and allowed to grow for 5 days, when the surviving fraction was determined from the incorporation of &#x0005b;<sup>3</sup>H&#x0005d;thymidine (0.4&#x02009;<em>&#x003bc;</em>Ci&#x02009;ml<sup>&#x02212;1</sup>, 6&#x02009;h).</p><p class="p p-last">For LiDEPT-dependent killing of the different cell lines, confluent monolayers of cells were exposed to varying concentrations of fusion proteins in complete growth medium (37&#x000b0;C, 30&#x02009;min), followed by three washes with growth medium to remove unbound protein. The cells were then incubated in growth medium containing different concentrations of CMDA (19&#x02009;h) and cell survival determined as described above.</p></div><div id="sec-a.t.e.g" class="sec sec-last"><p></p><h3 id="sec-a.t.e.gtitle" class="inline"><em>In vivo</em> stability studies </h3><p class="p p-first-last">All experiments were conducted in accordance with the United Kingdom Co-ordinating Committee on Cancer Research guidelines (<a href="#bib45" rid="bib45" class=" bibr popnode">Workman <em>et al</em>., 1998</a>). A group of 18 BALB&#x0002f;C nude mice was injected i.p. with 50 units of VEGF<sub>115</sub>CPG2(Q)3-H<sub>6</sub> in 200&#x02009;<em>&#x003bc;</em>l PBS. At intervals of 4, 8, 12, 16, 20, 24&#x02009;h after injection, triplicate blood samples were collected, and the CPG2 enzymic activity in the samples determined by assay against the model substrate methotrexate as previously described (<a href="#bib42" rid="bib42" class=" bibr popnode">Stribbling <em>et al</em>, 1997</a>)</p></div></div><div id="sec-a.t.f" class="tsec sec"><h2 class="head no_bottom_margin" id="sec-a.t.ftitle" style="text-transform: uppercase;">RESULTS</h2><div id="sec-a.t.f.b" class="sec sec-first"><p></p><h3 id="sec-a.t.f.btitle" class="inline">Construction of fusion proteins between VEGF and CPG2 </h3><p class="p p-first-last">Since CPG2 is a highly versatile protein, two classes of fusion protein between VEGF and CPG2 were considered. VEGF was fused either to the N-terminus or to the C-terminus of CPG2. For these studies, the aim was for these proteins to be secreted, so that the structurally important disulphide bonds of VEGF could form with high efficiency in the oxidising environment of the endoplasmic reticulum, and for glycosylation of VEGF to occur. Therefore, all constructs were provided with signal peptides. For those fusions in which VEGF was fused to the N-terminus of CPG2, the VEGF signal peptide was employed. For those fusion proteins that had CPG2 in the N-terminal position, the c-erbB2 signal peptide was employed, as this approach was previously shown to direct CPG2 to mammalian secretory pathways (<a href="#bib27" rid="bib27" class=" bibr popnode">Marais <em>et al</em>, 1997</a>). However, since CPG2 becomes glycosylated and consequently is inactivated in this pathway, a version of CPG2 (CPG2(Q)3) was used, in which all three glycosylation sites were mutated to prevent this event. The VEGF and CPG2(Q)3 were separated by either a nine amino-acid linker (EF(G)<sub>5</sub>TA) or a minimal linker (GS). A schematic diagram of the various constructs is shown in <a href="/pmc/articles/PMC2377106/figure/fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig2" rid-ob="ob-fig2" co-legend-rid="lgnd_fig2"><span>Figure 2</span></a>, and a description of their amino-acid structures is provided in <a href="/pmc/articles/PMC2377106/table/tbl1/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl1" rid-ob="ob-tbl1" co-legend-rid=""><span>Table 1</span></a>
. The final four C-terminal amino acids of VEGF<sub>165</sub> were deleted in VEGF<sub>161</sub>-CPG2(Q)3-H<sub>6</sub> since they contain three positively charged residues, which, if incorporated between fused VEGF and CPG2(Q)3 moieties, might be subject to recognition and cleavage by serine proteases such as trypsin. VEGF<sub>109</sub> arose accidentally as a PCR-generated truncation of VEGF<sub>165</sub>, and was retained for study. VEGF<sub>115</sub> was generated as a refinement of VEGF<sub>109</sub>, being truncated exactly at the junction of the heparin-binding domain. Finally, to facilitate purification, polyhistidine tags (H<sub>6</sub>) were fused to the C-termini of a number of the constructs to allow purification by nickel-agarose chromatography. The observed relative masses of the constructs were determined from their electrophoretic mobilities (<a href="/pmc/articles/PMC2377106/table/tbl1/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl1" rid-ob="ob-tbl1" co-legend-rid=""><span>Table 1</span></a>). In each case, the relative mass was similar to the value that would be predicted from the primary sequence.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="fig2" co-legend-rid="lgnd_fig2"><a href="/pmc/articles/PMC2377106/figure/fig2/" target="figure" rid-figpopup="fig2" rid-ob="ob-fig2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139987968040576"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2377106_88-6600911f2.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 88-6600911f2.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2377106/bin/88-6600911f2.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139987968040576"><a target="object" rel="noopener" href="/pmc/articles/PMC2377106/figure/fig2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig2"><div><a class="figpopup" href="/pmc/articles/PMC2377106/figure/fig2/" target="figure" rid-figpopup="fig2" rid-ob="ob-fig2">Figure 2</a></div><!--caption a7--><div class="caption"><p>Schematic representations of the structures of CPG2(Q)3-H<sub>6</sub> and fusion proteins. SP<sub>erb</sub> and SP<sub>v</sub>: signal peptides of c-erb B2 and VEGF, respectively. CPG2 23-415: amino acids 23&#x02013;415 of CPG2, showing the relative positions of the three asparagine to glutamine mutations (Q) required to avoid glycosylation and concomitant loss of CPG2 activity. H<sub>6</sub>: oligohistidine tag for purification by nickel-agarose chromatography. VEGF<sub>165</sub>, VEGF<sub>109</sub>, VEGF<sub>115</sub>, and VEGF<sub>161</sub>: amino acids 1&#x02013;165, 109, 115, and 161, respectively, of VEGF<sub>165</sub>. Black box: the relative position of the heparin-binding sequences of the longer forms of VEGF.</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="tbl1"><h3>Table 1</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Structures of the fusion proteins</strong></div><div class="xtable"><table frame="hsides" rules="groups" border="1" class="rendered small default_table"><thead valign="bottom"><tr><th align="left" valign="top" charoff="50" rowspan="1" colspan="1"><strong>Protein</strong></th><th align="left" valign="top" charoff="50" rowspan="1" colspan="1"><strong>Predicted primary sequence</strong></th><th align="center" valign="top" charoff="50" rowspan="1" colspan="1"><strong><em>M</em><sub>r</sub> (e)</strong></th><th align="center" valign="top" charoff="50" rowspan="1" colspan="1"><strong><em>M</em><sub>r</sub> (o)</strong></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">CPG2(Q)3-H<sub>6</sub></td><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">(c-erb B2 aa 1-27)-GS-(CPG2(Q)3 aa 23-415)-EF(H)<sub>6</sub>AS</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">43&#x02009;731</td><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">45&#x02009;000</td></tr><tr><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">CPG2(Q)3-VEGF<sub>165</sub></td><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">(c-erb B2 aa 1-27)-GS-(CPG2(Q)3 aa 23-415)-EF(G)<sub>5</sub>TA-(VEGF aa 1-165)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">62&#x02009;272</td><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">59&#x02013;61&#x02009;000</td></tr><tr><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">CPG2(Q)3-VEGF<sub>161</sub>-H<sub>6</sub></td><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">(c-erb B2 aa 1-27)-GS-(CPG2(Q)3 aa 23-415)-EF(G)<sub>5</sub>TA-(VEGF aa 1-161)-EF(H)<sub>6</sub>AS</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">63&#x02009;215</td><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">60&#x02013;62&#x02009;000</td></tr><tr><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">CPG2(Q)3-VEGF<sub>109</sub></td><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">(c-erb B2 aa 1-27)-GS-(CPG2(Q)3 aa 23-415)-EF(G)<sub>5</sub>TA-(VEGF aa 1-109)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">55&#x02009;657</td><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">53&#x02013;55&#x02009;000</td></tr><tr><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">CPG2(Q)3-VEGF<sub>109</sub>-H<sub>6</sub></td><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">(c-erb B2 aa 1-27)-GS-(CPG2(Q)3 aa 23-415)-EF(G)<sub>5</sub>TA-(VEGF aa 1-109)-EF(H)<sub>6</sub>AS</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">57&#x02009;135</td><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">54&#x02013;59&#x02009;000</td></tr><tr><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">VEGF<sub>161</sub>-CPG2(Q)3-H<sub>6</sub></td><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">(VEGF aa -26-161)-GS-(CPG2(Q)3 aa 23-415)-EF(H)<sub>6</sub>AS</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">61&#x02009;710</td><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">61&#x02013;63&#x02009;000</td></tr><tr><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub></td><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">(VEGF aa -26-115)-GS-(CPG2(Q)3 aa 23-415)-EF(H)<sub>6</sub>AS</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">56&#x02009;386</td><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">55&#x02013;61&#x02009;000</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm139987928550720"><a target="object" rel="noopener" href="/pmc/articles/PMC2377106/table/tbl1/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="tbfnote1"><p class="p p-first-last">Sequences of linkers between VEGF and CPG2-derived moieties and of oligohistidine tags for purification by nickel-agarose chromatography are given in the one-letter amino-acid code (22); <em>M</em><sub>r</sub> (e), expected relative subunit molecular weight; <em>M</em><sub>r</sub> (o), observed subunit molecular weight; aa, amino acids. c-erb B2 aa 1&#x02013;27 encode the c-erb B2 signal peptide. VEGF aa -26-1 encode the VEGF signal sequence.</p></div></div></div></div><div id="sec-a.t.f.c" class="sec"><p></p><h3 id="sec-a.t.f.ctitle" class="inline">Expression and characterisation of VEGF-CPG2 fusion proteins in mammalian cells </h3><p class="p p-first">As a first step, CPG2(Q)3-VEGF<sub>165</sub>, CPG2(Q)3-VEGF<sub>109</sub>, and CPG2(Q)3-H<sub>6</sub> were transiently expressed (see <a href="/pmc/articles/PMC2377106/table/tbl1/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl1" rid-ob="ob-tbl1" co-legend-rid=""><span>Table 1</span></a>, <a href="/pmc/articles/PMC2377106/figure/fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig2" rid-ob="ob-fig2" co-legend-rid="lgnd_fig2"><span>Figure 2</span></a>) in COS-7 cells. The filtered, conditioned growth media from the cells was tested for CPG2 activity, by examining its ability to hydrolyse the CPG2 substrate methotrexate (MTX). As expected, CPG2 activity was detected in the conditioned growth medium from CPG2(Q)3-VEGF<sub>165</sub>, CPG2(Q)3-VEGF<sub>109</sub>, and CPG2(Q)3-H<sub>6</sub> expressing cells, but not from control cells expressing <em>&#x003b2;</em>-galactosidase (<em>&#x003b2;</em>-gal)(<a href="/pmc/articles/PMC2377106/figure/fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig3" rid-ob="ob-fig3" co-legend-rid="lgnd_fig3"><span>Figure 3A</span></a>). There was also detectable CPG2 activity in detergent extracts from these cells (<a href="/pmc/articles/PMC2377106/figure/fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig3" rid-ob="ob-fig3" co-legend-rid="lgnd_fig3"><span>Figure 3A</span></a>). In Western blotting of the conditioned medium, CPG2 fusion proteins were not detected (data not shown). However, fusion proteins of the expected sizes (see <a href="/pmc/articles/PMC2377106/table/tbl1/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl1" rid-ob="ob-tbl1" co-legend-rid=""><span>Table 1</span></a>) were detected in immunoprecipitates of the conditioned medium that used a CPG2 specific antibody to capture the secreted CPG2-fusion proteins (<a href="/pmc/articles/PMC2377106/figure/fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig3" rid-ob="ob-fig3" co-legend-rid="lgnd_fig3"><span>Figure 3B</span></a>, lanes 2&#x02013;4). The VEGF moieties of the fusion proteins were then examined for binding to heparin. Conditioned medium from the cells was incubated with heparin-Sepharose, and the heparin-bound proteins were analysed by Western blotting. As expected, only CPG2(Q)3-VEGF<sub>165</sub> bound to heparin-Sepharose (<a href="/pmc/articles/PMC2377106/figure/fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig3" rid-ob="ob-fig3" co-legend-rid="lgnd_fig3"><span>Figure 3C</span></a>, lane 3), because CPG2(Q)3-VEGF<sub>109</sub> does not contain the heparin-binding domain (<a href="/pmc/articles/PMC2377106/figure/fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig3" rid-ob="ob-fig3" co-legend-rid="lgnd_fig3"><span>Figure 3c</span></a>, lane 4). <em>&#x003b2;</em>-gal and CPG2(Q)3-H<sub>6</sub> also failed to bind to heparin (<a href="/pmc/articles/PMC2377106/figure/fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig3" rid-ob="ob-fig3" co-legend-rid="lgnd_fig3"><span>Figure 3C</span></a>, lanes 1,2).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="fig3" co-legend-rid="lgnd_fig3"><a href="/pmc/articles/PMC2377106/figure/fig3/" target="figure" rid-figpopup="fig3" rid-ob="ob-fig3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139987924557536"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2377106_88-6600911f3.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 88-6600911f3.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2377106/bin/88-6600911f3.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139987924557536"><a target="object" rel="noopener" href="/pmc/articles/PMC2377106/figure/fig3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig3"><div><a class="figpopup" href="/pmc/articles/PMC2377106/figure/fig3/" target="figure" rid-figpopup="fig3" rid-ob="ob-fig3">Figure 3</a></div><!--caption a7--><div class="caption"><p>Expression of VEGF-CPG2 fusion proteins in mammalian cells. (<strong>A</strong>) CPG2 enzyme activity assays. COS-7 cells were transiently transfected with expression constructs for CPG2(Q)3-VEGF<sub>165</sub> (&#x025b4;,&#x025b5;), CPG(Q)3-VEGF<sub>109</sub> (&#x02666;,&#x022c4;), CPG2(Q)3-H<sub>6</sub> (&#x02022;,&#x025cb;) and <em>&#x003b2;</em>-galactosidase (&#x025aa;, &#x025a1;). CPG2 enzyme assays were performed on &#x0223c;1&#x0002f;30th of the conditioned growth medium (100&#x02009;<em>&#x003bc;</em>l; &#x025b5;,&#x022c4;,&#x025a1;,&#x025cb;) or detergent cell extracts (&#x0223c;10&#x02009;<em>&#x003bc;</em>g of protein; &#x025b4;,&#x02666;,&#x025aa;,&#x02022;). Data are means of three separate transfections, except for <em>&#x003b2;</em>-galactosidase expression, which are mean data from two separate transfections. (<strong>B</strong>) Western blotting of fusion proteins. Proteins from the conditioned medium from COS cells expressing <em>&#x003b2;</em>-galactosidase (<em>&#x003b2;</em>-gal) (lane 1), CPG2(Q)3-H<sub>6</sub> (lane 2), CPG2(Q)3-VEGF<sub>165</sub> (lane 3), and CPG(Q)3-VEGF<sub>109</sub> (lane 4) were immunoprecipitated using a polyclonal antibody to CPG2 and subjected to Western blotting for fusion protein expression. The positions of migration of size markers (&#x000d7; 10<sup>&#x02212;3</sup>) are shown to the right and arrowheads to the left identify the proteins as follows: upper, CPG2(Q)3-VEGF<sub>165</sub>, middle CPG2(Q)3-VEGF<sub>109</sub>, and lower, CPG2(Q)3-H<sub>6</sub>. The figure is a composite of two separate segments of one gel. (<strong>C</strong>) Heparin binding of VEGF-CPG2 fusion proteins. Conditioned medium from COS-7 cells transiently expressing <em>&#x003b2;</em>-gal (lane 1), CPG2(Q)3-H<sub>6</sub> (lane 2), CPG2(Q)3-VEGF<sub>165</sub> (lane 3), and CPG2(Q)3-VEGF<sub>109</sub> (lane 4) was analysed for the ability of the fusion proteins to bind to heparin-Sepharose. Western blotting revealed the bound proteins and the positions of migration of size markers (&#x000d7; 10<sup>&#x02212;3</sup>) are shown to the left. The arrowhead to the right points towards the position of migration of CPG2(Q)3-VEGF<sub>165</sub>. The figure is a composite of two separate segments of one gel.</p></div></div></div><p class="p p-last">Next, the expression of the additional fusion proteins was tested. VEGF<sub>161</sub>-CPG2(Q)3-H<sub>6</sub> and VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub> are also secreted and accumulate in growth medium to higher levels than the fusions with the N-terminal CPG2(Q)3 moiety (<a href="/pmc/articles/PMC2377106/table/tbl2/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl2" rid-ob="ob-tbl2" co-legend-rid=""><span>Table 2</span></a>
). In all cases, the secreted product accumulates to greater amounts in the medium than in the cell extracts (<a href="/pmc/articles/PMC2377106/table/tbl2/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl2" rid-ob="ob-tbl2" co-legend-rid=""><span>Table 2</span></a>). VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub> is secreted particularly efficiently, with over 98&#x00025; of the total expressed activity found in the growth medium. This protein is also the most highly expressed of all the CPG2-VEGF fusion proteins tested. To estimate the specific activity of the CPG2 moiety of the fusion proteins, the concentrations of CPG2 protein in the conditioned media were measured using quantitative Western blotting. The specific activities of the different fusion proteins could then be estimated using the standard enzyme assay. All of the fusion proteins had levels of enzyme activity equivalent to, or higher than the nonfused secreted form of CPG2(Q)3 (CPG2(Q)3-H<sub>6</sub>; <a href="/pmc/articles/PMC2377106/table/tbl2/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl2" rid-ob="ob-tbl2" co-legend-rid=""><span>Table 2</span></a>). Indeed, the fusions with the shorter forms of VEGF both had greater activity (approximately 140&#x00025;) than secreted CPG2(Q)3. However, there does not appear to be any difference in CPG2 activity when the relative orientation of the VEGF- and CPG2-derived moieties is compared. Quantitative Western blotting was also used to determine the relative efficiency of binding of the fusion proteins to heparin-Sepharose as in <a href="/pmc/articles/PMC2377106/table/tbl2/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl2" rid-ob="ob-tbl2" co-legend-rid=""><span>Table 2</span></a>. CPG2(Q)3-VEGF<sub>165</sub> and VEGF<sub>161</sub>-CPG2(Q)3-H<sub>6</sub> both bound to heparin with similar efficiencies, whereas the binding of the fusions with the shorter forms of VEGF was severely reduced (<a href="/pmc/articles/PMC2377106/table/tbl2/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl2" rid-ob="ob-tbl2" co-legend-rid=""><span>Table 2</span></a>).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="tbl2"><h3>Table 2</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Expression of fusion proteins between CPG2(Q)3 and VEGF in COS-7 cells</strong></div><div class="xtable"><table frame="hsides" rules="groups" border="1" class="rendered small default_table"><thead valign="bottom"><tr><th align="left" valign="top" charoff="50" rowspan="1" colspan="1">&#x000a0;</th><th colspan="2" align="center" valign="top" charoff="50" rowspan="1"><strong>Total CPG2 activity (U&#x02009;well<sup>&#x02212;1</sup>) in:</strong><hr /></th><th align="center" valign="top" charoff="50" rowspan="1" colspan="1"><strong>Relative CPG2-specific</strong></th><th align="center" valign="top" charoff="50" rowspan="1" colspan="1"><strong>Relative heparin-binding</strong></th></tr><tr><th align="left" valign="top" charoff="50" rowspan="1" colspan="1"><strong>Protein</strong></th><th align="center" valign="top" charoff="50" rowspan="1" colspan="1"><strong>Cells</strong></th><th align="center" valign="top" charoff="50" rowspan="1" colspan="1"><strong>Medium</strong></th><th align="center" valign="top" charoff="50" rowspan="1" colspan="1"><strong>activity (&#x00025;)</strong></th><th align="center" valign="top" charoff="50" rowspan="1" colspan="1"><strong>activity (&#x00025;)</strong></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">CPG2(Q)3-VEGF<sub>165</sub></td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">0.0023 (&#x000b1;0.0005)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">0.021 (&#x000b1;0.001)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">110 (&#x000b1;11)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">100</td></tr><tr><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">CPG2(Q)3-VEGF<sub>109</sub></td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">0.0077 (&#x000b1;0.0005)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">0.023 (&#x000b1;0.001)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">143 (&#x000b1;13)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">2.1</td></tr><tr><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">VEGF<sub>161</sub>-CPG2(Q)3-H<sub>6</sub></td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">0.0098 (&#x000b1;0.0013)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">0.037 (&#x000b1;0.009)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">102 (&#x000b1;13)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">99</td></tr><tr><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub></td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">0.0009 (&#x000b1;0.0001)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">0.066 (&#x000b1;0.011)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">140 (&#x000b1;19)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">10.2</td></tr><tr><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">CPG2(Q)3-H<sub>6</sub></td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">0.084 (&#x000b1;0.10)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">0.139 (&#x000b1;0.004)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">100</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">2.4</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm139987921291936"><a target="object" rel="noopener" href="/pmc/articles/PMC2377106/table/tbl2/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="tbfnote2"><p class="p p-first-last">The CPG2 in conditioned media and cell extracts was measured using quantitative Western blotting to estimate the relative protein levels by phosphorimaging. The relative activity of the different fusion proteins could then be estimated using the standard enzyme assay. Quantitative Western blotting was also used to determine the relative efficiency of binding of the fusion proteins to heparin-Sepharose. Data shown for measurements of total activity and relative activity are means (&#x000b1;s.d.) of three transfections.</p></div></div></div></div><div id="sec-a.t.f.d" class="sec"><p></p><h3 id="sec-a.t.f.dtitle" class="inline">Expression of VEGF-CPG2 fusion proteins in Sf9 cells </h3><p class="p p-first">The above data establish that CPG2-VEGF fusion proteins can be produced that retain CPG2 enzyme activity and heparin binding in the VEGF moiety. These fusion proteins were tested for binding to the VEGF receptor, VEGFR2, to ascertain whether they could mediate killing of mammalian cells. To perform these experiments, large amounts of fusion protein were expressed in Sf9 insect cells.</p><p>Baculoviruses encoding CPG2(Q)3-H<sub>6</sub>, VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub>, CPG2(Q)3-VEGF<sub>109</sub>-H<sub>6</sub>, and VEGF<sub>161</sub>-CPG2(Q)3-H<sub>6</sub>, were generated and used to infect Sf9 insect cells. The fusion proteins were purified from conditioned growth media by single-step nickel-agarose affinity chromatography, and were judged to be 99&#x00025; pure by silver staining (data not shown) except for VEGF<sub>161</sub>-CPG2(Q)3-H<sub>6</sub>, which required an extra heparin affinity chromatography step to reach a similar degree of purity (data not shown).</p><p>CPG2 is a homodimeric protein that is denatured by heat treatment in the presence of SDS, and so migrates as monomers in polyacrylamide gels following heat treatment (<a href="#bib38" rid="bib38" class=" bibr popnode">Spooner <em>et al</em>, 2000</a>). VEGF is also a homodimer, but it is stabilised by disulphide linkage. To assess whether the VEGF moieties were stabilised by disulphide linkages, the different fusion proteins were subjected to heat treatment under reducing or nonreducing conditions. As expected, CPG2(Q)3-H<sub>6</sub> migrated as a monomer under both reducing and nonreducing conditions (<a href="/pmc/articles/PMC2377106/figure/fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig4" rid-ob="ob-fig4" co-legend-rid="lgnd_fig4"><span>Figure 4</span></a>, lanes 1, 5). VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub>, CPG2(Q)3-VEGF<sub>109</sub>-H<sub>6</sub>, and VEGF<sub>161</sub>-CPG2(Q)3-H<sub>6</sub> also migrated as monomers under reducing conditions (<a href="/pmc/articles/PMC2377106/figure/fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig4" rid-ob="ob-fig4" co-legend-rid="lgnd_fig4"><span>Figure 4</span></a>, lanes 2&#x02013;4), but under nonreducing conditions migrated with sizes that were consistent with dimerization (<a href="/pmc/articles/PMC2377106/figure/fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig4" rid-ob="ob-fig4" co-legend-rid="lgnd_fig4"><span>Figure 4</span></a>, lanes 6&#x02013;8). A contaminating protein, presumably a degradation product related to CPG2, is routinely found in preparations of VEGF<sub>161</sub>-CPG2(Q)3-H<sub>6</sub> (<a href="/pmc/articles/PMC2377106/figure/fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig4" rid-ob="ob-fig4" co-legend-rid="lgnd_fig4"><span>Figure 4</span></a>, lanes 4, 8). We conclude that the VEGF moieties in these fusion proteins are stabilised by disulphide linkages. These fusion proteins were then tested for the ability to bind to the ligand-binding domain of VEGFR2. For these studies, the extracellular and transmembrane domains of VEGFR2 were expressed as a 9E10-tagged protein in insect cells. This construct, which has the kinase domain (KD) of VEGFR2 deleted, included codons &#x02212;20&#x02013;809 of VEGFR2 fused to a 9E10 monoclonal antibody epitope (VEGFR2(&#x00394;KD)m).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="fig4" co-legend-rid="lgnd_fig4"><a href="/pmc/articles/PMC2377106/figure/fig4/" target="figure" rid-figpopup="fig4" rid-ob="ob-fig4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139987923487488"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2377106_88-6600911f4.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 88-6600911f4.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2377106/bin/88-6600911f4.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139987923487488"><a target="object" rel="noopener" href="/pmc/articles/PMC2377106/figure/fig4/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig4"><div><a class="figpopup" href="/pmc/articles/PMC2377106/figure/fig4/" target="figure" rid-figpopup="fig4" rid-ob="ob-fig4">Figure 4</a></div><!--caption a7--><div class="caption"><p>VEGF-CPG2(Q)3 and CPG2(Q)3-VEGF fusion proteins are disulphide-linked dimers. Affinity-purified CPG2(Q)3-H<sub>6</sub>, VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub>, CPG2(Q)3-VEGF<sub>109</sub>-H<sub>6</sub>, and VEGF<sub>161</sub>-CPG2(Q)3-H<sub>6</sub> proteins were heated in either reducing (lanes 1&#x02013;4) or nonreducing (lanes 5&#x02013;8) conditions, subjected to polyacrylamide gel electrophoresis and were identified after immunoblotting using a rabbit anti-CPG2 serum and <sup>125</sup>I-Protein A. Closed arrowheads show the positions of migration of monomers and open arrowheads show the positions of migration of dimers. The positions of migration of size markers (&#x000d7; 10<sup>&#x02212;3</sup>) are shown to the right. Asterisks mark the positions of migration of a breakdown product derived from VEGF<sub>161</sub>-CPG2(Q)3-H<sub>6</sub> protein.</p></div></div></div><p>For VEGF binding studies, VEGFR2(&#x00394;KD)m in a 96-well plate ELISA format was used. The plates were seeded with the 9E10 monoclonal antibody and VEGFR2(&#x00394;KD)m was captured on the immobilised 9E10 antibody. &#x0005b;<sup>125</sup>I&#x0005d;VEGF bound to this immobilised VEGFR2(&#x00394;KD)m with high affinity (<em>K</em><sub>d</sub>&#x0223c;0.5&#x02009;n<span class="small-caps">M</span>). The fusion proteins were incubated with the captured VEGFR2(&#x00394;KD)m and binding was determined. All of the fusion proteins bound with similar affinities, with <em>K</em><sub>d</sub> values of approximately 0.5&#x02013;1.1&#x02009;n<span class="small-caps">M</span> (<a href="/pmc/articles/PMC2377106/figure/fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig5" rid-ob="ob-fig5" co-legend-rid="lgnd_fig5"><span>Figure 5A</span></a>, <a href="/pmc/articles/PMC2377106/table/tbl3/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl3" rid-ob="ob-tbl3" co-legend-rid=""><span>Table 3</span></a>
).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="fig5" co-legend-rid="lgnd_fig5"><a href="/pmc/articles/PMC2377106/figure/fig5/" target="figure" rid-figpopup="fig5" rid-ob="ob-fig5"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139987917799952"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2377106_88-6600911f5.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 88-6600911f5.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2377106/bin/88-6600911f5.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139987917799952"><a target="object" rel="noopener" href="/pmc/articles/PMC2377106/figure/fig5/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig5"><div><a class="figpopup" href="/pmc/articles/PMC2377106/figure/fig5/" target="figure" rid-figpopup="fig5" rid-ob="ob-fig5">Figure 5</a></div><!--caption a7--><div class="caption"><p><em>In vitro</em> binding assays: (<strong>A</strong>) ELISA showing binding of &#x0005b;<sup>125</sup>I&#x0005d;VEGF (&#x02022;), VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub> (&#x025b5;), VEGF<sub>161</sub>-CPG2(Q)3-H<sub>6</sub> (&#x025a1;),or CPG2(Q)3-VEGF<sub>109</sub>-H<sub>6</sub> (&#x022c4;) to VEGFR2(&#x00394;KD)m. (<strong>B</strong>) RIA showing competition of CPG2(Q)3-H<sub>6</sub> (&#x025cb;), VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub> (&#x025b5;), VEGF<sub>161</sub>-CPG2(Q)3-H<sub>6</sub> (&#x025a1;), CPG2(Q)3-VEGF<sub>109</sub>-H<sub>6</sub> (&#x022c4;), or VEGF<sub>165</sub> (&#x02022;) with &#x0005b;<sup>125</sup>I&#x0005d;VEGF for VEGFR2(&#x00394;KD)m. (<strong>C</strong>) Kinetics of binding of VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub> (&#x025b5;),VEGF<sub>161</sub>-CPG2(Q)3-H<sub>6</sub> (&#x025a1;),or CPG2(Q)3-VEGF<sub>109</sub>-H<sub>6</sub> (&#x022c4;) to VEGFR2(&#x00394;KD)m captured by immobilised 9E10 monoclonal antibody, measured by ELISA.</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="tbl3"><h3>Table 3</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Binding characteristics of fusion proteins between CPG2(Q)3 and VEGF expressed in insect cells</strong></div><div class="xtable"><table frame="hsides" rules="groups" border="1" class="rendered small default_table"><thead valign="bottom"><tr><th align="left" valign="top" charoff="50" rowspan="1" colspan="1"><strong>Protein</strong></th><th align="center" valign="top" charoff="50" rowspan="1" colspan="1"><strong>ELISA <em>K</em><sub>d</sub> (n<span class="small-caps">M</span>)</strong></th><th align="center" valign="top" charoff="50" rowspan="1" colspan="1"><strong>Competition RIA <em>K</em><sub>d</sub> (n<span class="small-caps">M</span>)</strong></th><th align="center" valign="top" charoff="50" rowspan="1" colspan="1"><strong>50&#x00025; binding <em>t</em><sub>50</sub> (s)</strong></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">CPG2(Q)3-VEGF<sub>109</sub>-H<sub>6</sub></td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">0.75 (&#x000b1;0.05)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">1.3 (&#x000b1;0.1)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">332</td></tr><tr><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">VEGF<sub>161</sub>-CPG2(Q)3-H<sub>6</sub></td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">1.06 (&#x000b1;0.66)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">3.3 (&#x000b1;0.3)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">330</td></tr><tr><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub></td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">0.51 (&#x000b1;0.08)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">9.6 (&#x000b1;0.6)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">77</td></tr><tr><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">CPG2(Q)3-H<sub>6</sub></td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">ND</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">No competition</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">ND</td></tr><tr><td align="left" valign="top" charoff="50" rowspan="1" colspan="1">&#x0005b;<sup>125</sup>I&#x0005d;-VEGF</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">0.51 (&#x000b1;0.06)</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">ND</td><td align="center" valign="top" charoff="50" rowspan="1" colspan="1">ND</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm139987917795968"><a target="object" rel="noopener" href="/pmc/articles/PMC2377106/table/tbl3/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="tbfnote3"><p class="p p-first-last">VEGFR2(&#x00394;KD)m was captured on the 9E10 antibody immobilised in 96-well plates. The fusion proteins were incubated with the captured VEGFR2(&#x00394;KD)m and binding was determined. We also used a competition RIA where binding of &#x0005b;<sup>125</sup>I&#x0005d;VEGF to VEGFR2(&#x00394;KD)m occurs in the presence of competing fusion proteins. The rate of binding was also determined, by exposing the fusion proteins to immobilised VEGFR2(&#x00394;KD)m for short times before washing out the protein and measuring how much fusion protein was bound.</p></div></div></div><p class="p p-last">A competition RIA was used where binding of &#x0005b;<sup>125</sup>I&#x0005d;VEGF to VEGFR2(&#x00394;KD)m occurs in the presence of competing fusion proteins. Using this analysis, the binding of the fusion proteins was estimated to be slightly higher, with <em>K</em><sub>d</sub> values from 1.3&#x02013;9.6&#x02009;n<span class="small-caps">M</span> (<a href="/pmc/articles/PMC2377106/figure/fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig5" rid-ob="ob-fig5" co-legend-rid="lgnd_fig5"><span>Figure 5B</span></a>, <a href="/pmc/articles/PMC2377106/table/tbl3/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl3" rid-ob="ob-tbl3" co-legend-rid=""><span>Table 3</span></a>). CPG2(Q)3-H<sub>6</sub> protein did not compete for &#x0005b;<sup>125</sup>I&#x0005d;VEGF binding in this assay (<a href="/pmc/articles/PMC2377106/table/tbl3/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl3" rid-ob="ob-tbl3" co-legend-rid=""><span>Table 3</span></a>). Finally, the rate of binding was measured, by exposing the fusion proteins to immobilised VEGFR2(&#x00394;KD)m for short times before washing out the protein and measuring how much fusion protein was bound. VEGF<sub>115</sub>CPG2(Q)3-H<sub>6</sub> reaching half-maximal binding in 77&#x02009;s (<a href="/pmc/articles/PMC2377106/figure/fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig5" rid-ob="ob-fig5" co-legend-rid="lgnd_fig5"><span>Figure 5C</span></a>, <a href="/pmc/articles/PMC2377106/table/tbl3/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl3" rid-ob="ob-tbl3" co-legend-rid=""><span>Table 3</span></a>). The binding of CPG2(Q)3VEGF<sub>109</sub>-H<sub>6</sub> and VEGF<sub>161</sub>CPG2(Q)3-H<sub>6</sub> was somewhat slower, reaching half-maximal binding after about 330&#x02009;s.</p></div><div id="sec-a.t.f.e" class="sec"><p></p><h3 id="sec-a.t.f.etitle" class="inline">Kinetic analysis of VEGF<sub>115</sub>CPG2(Q)3-H<sub>6</sub> </h3><p class="p p-first-last">Taken together, the above data suggest that VEGF<sub>115</sub>CPG2(Q)3-H<sub>6</sub> is the most suitable candidate for the LiDEPT approach. It displays rapid binding to receptor, is secreted efficiently, is the most highly expressed, and has the highest specific activity. We therefore subjected this protein to detailed kinetic analysis for the CPG2 activity. CPG2 produced in bacteria has a <em>K</em><sub>m</sub> for MTX of 8&#x02009;<em>&#x003bc;</em><span class="small-caps">M</span> (<a href="#bib35" rid="bib35" class=" bibr popnode">Sherwood <em>et al</em>, 1985</a>). Similarly, CPG2 expressed in the cytosol of mammalian and insect cells also have <em>K</em><sub>m</sub> values for MTX of approximately 7&#x02009;<em>&#x003bc;</em><span class="small-caps">M</span> (<a href="#bib30" rid="bib30" class=" bibr popnode">Napier <em>et al</em>, 2000</a>). Secreted CPG2(Q)3-H<sub>6</sub>, has a <em>K</em><sub>m</sub> of 29.5&#x02009;<em>&#x003bc;</em><span class="small-caps">M</span> MTX and VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub> a <em>K</em><sub>m</sub> of 37.5&#x02009;<em>&#x003bc;</em><span class="small-caps">M</span> MTX (mean of two independent preparations). Again, a slight increase in catalytic activity was noted for this fusion protein (140&#x00025;, <a href="/pmc/articles/PMC2377106/table/tbl2/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl2" rid-ob="ob-tbl2" co-legend-rid=""><span>Table 2</span></a>). Thus, the fusion of VEGF domains to CPG2(Q)3 does not appear to affect the affinity for substrate as compared to secreted CPG2(Q)3, and can result in a moderate increase in catalytic activity.</p></div><div id="sec-a.t.f.f" class="sec"><p></p><h3 id="sec-a.t.f.ftitle" class="inline">Fusion proteins of CPG2 and VEGF can direct cytotoxicity to VEGFR2-positive cells </h3><p class="p p-first">VEGF-CPG2 fusion proteins were next assessed for their ability to generate a targeted increase in the cytotoxicity of CMDA towards HU-V-EC cells, which express receptors for VEGF. Initially, the sensitivity of HU-V-EC cells to CMDA alone was established. The IC<sub>50</sub> of CMDA in HU-V-EC cells was 1587 (&#x000b1;) 224&#x02009;<em>&#x003bc;</em><span class="small-caps">M</span> (<a href="/pmc/articles/PMC2377106/figure/fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig6" rid-ob="ob-fig6" co-legend-rid="lgnd_fig6"><span>Figure 6A</span></a>). The highest dose of CMDA that produced no cytotoxicity in HU-V-EC cells was 500&#x02009;<em>&#x003bc;</em><span class="small-caps">M</span> (open arrowhead, <a href="/pmc/articles/PMC2377106/figure/fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig6" rid-ob="ob-fig6" co-legend-rid="lgnd_fig6"><span>Figure 6A</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="fig6" co-legend-rid="lgnd_fig6"><a href="/pmc/articles/PMC2377106/figure/fig6/" target="figure" rid-figpopup="fig6" rid-ob="ob-fig6"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139987931146704"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2377106_88-6600911f6.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 88-6600911f6.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2377106/bin/88-6600911f6.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139987931146704"><a target="object" rel="noopener" href="/pmc/articles/PMC2377106/figure/fig6/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig6"><div><a class="figpopup" href="/pmc/articles/PMC2377106/figure/fig6/" target="figure" rid-figpopup="fig6" rid-ob="ob-fig6">Figure 6</a></div><!--caption a7--><div class="caption"><p>Cytotoxicity studies. (<strong>A</strong>) Sensitivity of HU-V-EC (&#x025cb;) and SK-OV-3 cells (&#x02022;) to treatment with the prodrug CMDA. Arrowheads show the maximum concentrations of CMDA that the HU-V-EC (&#x025bf;) and SK-OV-3 cells (&#x025be;) cells can tolerate without measurable cell death. (<strong>B</strong>) Effect on the survival of HU-V-EC cells of preincubation with CPG2(Q)3-H<sub>6</sub>, CPG2(Q)3-VEGF109-H<sub>6</sub>, or VEGF115CPG2(Q)3-H<sub>6</sub>, at doses of 0.5&#x02009;nm (plain bars), 5&#x02009;nm (shaded bars), or 50&#x02009;nm (filled bars) and subsequent treatment with 500&#x02009;<em>&#x003bc;</em><span class="small-caps">M</span> CMDA. (<strong>C</strong>) Sensitivity of HU-V-EC and SK-OV-3 cells to CMDA challenge (500 and 1000&#x02009;<em>&#x003bc;</em><span class="small-caps">M,</span> respectively) after a 30&#x02009;min incubation with 50&#x02009;nm VEGF<sub>115</sub>CPG2(Q)3-H<sub>6</sub>.</p></div></div></div><p>Confluent HU-V-EC cells were incubated with three doses of VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub>, CPG2(Q)3-VEGF<sub>109</sub>-H<sub>6</sub>, or CPG2(Q)3-H<sub>6</sub> (50, 5, or 0.5&#x02009;n<span class="small-caps">M</span>) in complete growth medium for 30&#x02009;min, after which the unbound proteins were removed by rinsing &#x000d7; 3. These cells were then incubated in the previously established nontoxic dose of CMDA (500&#x02009;<em>&#x003bc;</em><span class="small-caps">M</span>), and cell survival then determined in our standard assay. Only a slight increase in cytotoxicity was seen with increasing concentrations of CPG2(Q)3-H<sub>6</sub> (<a href="/pmc/articles/PMC2377106/figure/fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig6" rid-ob="ob-fig6" co-legend-rid="lgnd_fig6"><span>Figure 6B</span></a>). By contrast, a marked protein-dose-dependant reduction in survival was seen following exposure to VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub>, and VEGF<sub>109</sub>-CPG2(Q)3-H<sub>6</sub>, indicative of these proteins having resisted rinsing, being bound, presumably to the VEGFRs of the cells. To confirm that this increased cytotoxicity is indeed the result of binding to VEGFRs, a similar experiment was performed, comparing HU-V-EC cells to SK-OV-3 cells, which by contrast do not express VEGFRs. As previously, the sensitivity to CMDA alone was first established. The IC<sub>50</sub> of CMDA in SK-OV-3 cells was 4323 (&#x000b1;473)&#x02009;<em>&#x003bc;</em><span class="small-caps">M</span> (<a href="/pmc/articles/PMC2377106/figure/fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig6" rid-ob="ob-fig6" co-legend-rid="lgnd_fig6"><span>Figure 6A</span></a>) very similar to our previous estimate (<a href="#bib27" rid="bib27" class=" bibr popnode">Marais <em>et al</em>, 1997</a>). The highest dose of CMDA that produced no cytotoxicity in SK-OV-3 cells was 1000&#x02009;<em>&#x003bc;</em><span class="small-caps">M</span> (filled arrowhead, <a href="/pmc/articles/PMC2377106/figure/fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig6" rid-ob="ob-fig6" co-legend-rid="lgnd_fig6"><span>Figure 6A</span></a>). HU-V-EC and SK-OV-3 cells were treated with 50&#x02009;n<span class="small-caps">M</span> VEGF<sub>115</sub>-CPG2-H<sub>6</sub>, washed three times, and then treated with subcytotoxic doses of CMDA (500 and 1000&#x02009;<em>&#x003bc;</em><span class="small-caps">M</span>, respectively). This results in an increase in cytotoxicity (75&#x00025;) in HU-V-EC cells, but not in SK-OV-3 cells (<a href="/pmc/articles/PMC2377106/figure/fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig6" rid-ob="ob-fig6" co-legend-rid="lgnd_fig6"><span>Figure 6</span></a>), confirming that the fusion protein is binding to VEGFRs on HU-V-EC cells.</p><p class="p p-last">Thus, the cytotoxic drug is being generated from concentrations of CMDA similar to those achieved in the plasma of human patients during a phase I&#x0002f;II ADEPT clinical trial (<a href="#bib28" rid="bib28" class=" bibr popnode">Martin <em>et al</em>, 1997</a>).</p></div><div id="sec-a.t.f.g" class="sec sec-last"><p></p><h3 id="sec-a.t.f.gtitle" class="inline">Stability of fusion protein <em>in vivo</em> </h3><p class="p p-first-last">When VEGF<sub>115</sub>-CPG2-H<sub>6</sub> was injected i.p. into mice, the plasma levels of enzymic CPG2 activity decayed with a one-phase exponential half-life of 3&#x02009;h (<a href="/pmc/articles/PMC2377106/figure/fig7/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig7" rid-ob="ob-fig7" co-legend-rid="lgnd_fig7"><span>Figure 7</span></a>), similar to that previously observed (4&#x02009;h) with an antibody fragment-CPG2 conjugate, known as A5B7-F(ab')2-CPG2, used in ADEPT (<a href="#bib34" rid="bib34" class=" bibr popnode">Sharma <em>et al</em>, 1990</a>). The presence of enzymic activity implies the presence of intact dimers, and we anticipate that this stability in the circulation will also allow localisation similar to that seen in ADEPT (<a href="#bib30" rid="bib30" class=" bibr popnode">Napier <em>et al</em>, 2000</a>), a therapy now in phase I&#x0002f;II trial.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="fig7" co-legend-rid="lgnd_fig7"><a href="/pmc/articles/PMC2377106/figure/fig7/" target="figure" rid-figpopup="fig7" rid-ob="ob-fig7"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139987930093904"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2377106_88-6600911f7.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 88-6600911f7.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2377106/bin/88-6600911f7.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139987930093904"><a target="object" rel="noopener" href="/pmc/articles/PMC2377106/figure/fig7/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig7"><div><a class="figpopup" href="/pmc/articles/PMC2377106/figure/fig7/" target="figure" rid-figpopup="fig7" rid-ob="ob-fig7">Figure 7</a></div><!--caption a7--><div class="caption"><p>Balb&#x0002f;c nude mice were injected i.p. with 50&#x02009;U CPG2. At intervals as indicated, blood was collected and analysed for CPG2 activity. The line is a fit to a one-phase exponential decay with a half-life of 2.8&#x02009;h. Each point represents the mean of three separate determinations&#x000b1;s.e.m.</p></div></div></div></div></div><div id="sec-a.t.g" class="tsec sec"><h2 class="head no_bottom_margin" id="sec-a.t.gtitle" style="text-transform: uppercase;">DISCUSSION</h2><p class="p p-first">The approach of targeting cytotoxicity via a fusion protein has a long and successful history. Prime examples are the fusions of cell-binding ligands with the catalytic subunit of <em>Pseudomonas</em> exotoxin A, which lacks cell-binding activity. The first example was fusion with transforming growth factor-type alpha (<a href="#bib9" rid="bib9" class=" bibr popnode">Chaudhary <em>et al</em>, 1987</a>). Since then, a wide range of fusion partners have been considered, including interleukins (<a href="#bib10" rid="bib10" class=" bibr popnode">Chaudhary <em>et al</em>, 1989</a>; <a href="#bib4" rid="bib4" class=" bibr popnode">Batra <em>et al</em>, 1991</a>, <a href="#bib5" rid="bib5" class=" bibr popnode">1992</a>; <a href="#bib23" rid="bib23" class=" bibr popnode">Kreitman <em>et al</em>, 1992</a>; <a href="#bib17" rid="bib17" class=" bibr popnode">Gawlak <em>et al</em>, 1993</a>; <a href="#bib24" rid="bib24" class=" bibr popnode">Kunwar <em>et al</em>, 1993</a>; <a href="#bib14" rid="bib14" class=" bibr popnode">Francisco <em>et al</em>, 1995</a>; <a href="#bib36" rid="bib36" class=" bibr popnode">Siegall <em>et al</em>, 1995</a>), other growth factors (<a href="#bib33" rid="bib33" class=" bibr popnode">Prior <em>et al</em>, 1991</a>; <a href="#bib17" rid="bib17" class=" bibr popnode">Gawlak <em>et al</em>, 1993</a>; <a href="#bib24" rid="bib24" class=" bibr popnode">Kunwar <em>et al</em>, 1993</a>; <a href="#bib29" rid="bib29" class=" bibr popnode">Mesri <em>et al</em>, 1993</a>; <a href="#bib36" rid="bib36" class=" bibr popnode">Siegall <em>et al</em>, 1995</a>), single chain antibody fragments (<a href="#bib10" rid="bib10" class=" bibr popnode">Chaudhary <em>et al</em>, 1989</a>; <a href="#bib4" rid="bib4" class=" bibr popnode">Batra <em>et al</em>, 1991</a>, <a href="#bib5" rid="bib5" class=" bibr popnode">1992</a>; <a href="#bib23" rid="bib23" class=" bibr popnode">Kreitman <em>et al</em>, 1992</a>; <a href="#bib14" rid="bib14" class=" bibr popnode">Francisco <em>et al</em>, 1995</a>) and hormones (<a href="#bib6" rid="bib6" class=" bibr popnode">Ben Yehudah <em>et al</em>, 1999</a>). Such studies have demonstrated that a wide range of ligands can be regarded as potential antitumour-targeting devices, and a wide range of cellular receptors can be viewed as targets. Furthermore, complete regressions have been recorded (<a href="#bib8" rid="bib8" class=" bibr popnode">Brinkmann <em>et al</em>, 1991</a>), underlining the success of this approach.</p><p>We considered the VEGFRs as targets for an approach to deliver not a toxin, but an enzyme with catalytic activity capable of converting large numbers of molecules of a nontoxic prodrug to a toxic drug. We show that VEGF-CPG2 fusion proteins retain activities of both parental molecules, irrespective of whether they are the N- or C-terminal moiety, and that they retain these characteristics if either very short or longer linkers are used to join them. If provided with either the VEGF signal sequence or the c-erb B2 signal sequence, all the fusions are secreted into the growth medium, from where they could be purified to near homogeneity by single-step nickel-agarose chromatography. All the fusions are disulphide-linked dimers as expected. Those with shorter VEGF moieties show a moderate (1.4-fold) increase in CPG2 activity. Native CPG2 is active as a dimeric protein, while CPG2(Q)3 has a comparatively reduced activity owing to a reduction in dimer stability (<a href="#bib38" rid="bib38" class=" bibr popnode">Spooner <em>et al</em>, 2000</a>). It is therefore possible that fusion with the shorter forms of VEGF compensates for the deleterious effect of the (Q)3 mutations by improving dimer stability. These fusion proteins bind VEGFR2 domains with an affinity close to that of VEGF, and one in particular, VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub> binds very rapidly. It retains specificity for VEGFR2, and can differentiate between endothelial cells that express VEGFRs (HU-V-EC) and those that do not (SK-OV-3). Once delivered to cells, the proteins can convert the prodrug CMDA to its toxic metabolite, thus killing targeted cells.</p><p>Although expression of VEGFR2 is high in the neoangiogenic regions of tumour vasculature, some normal organs also express VEGFRs (<a href="#bib7" rid="bib7" class=" bibr popnode">Blaauwgeers <em>et al</em>, 1999</a>; <a href="#bib22" rid="bib22" class=" bibr popnode">Kim <em>et al</em>, 1999</a>). Both receptors are expressed predominantly in endothelial cells, but a few additional cell types express one or both of these receptors. Despite these caveats, recognition of VEGFRs as therapeutic targets for cancer is likely to be of value. Indeed, VEGF-diphtheria toxin fusion proteins are toxic to endothelial cells and Kaposi's sarcoma cell lines, inhibit angiogenesis and retard tumour growth, in a VEGFR-dependent manner (6). Since nearly all tumours induce local angiogenesis with associated high levels of VEGFR expression, VEGF-derived targeting molecules may have wide application for therapy.</p><p>VEGF-CPG2 fusion proteins should direct CPG2 activity to cells expressing VEGFRs, principally those activated endothelial cells in tumour vasculature. Once localised, these proteins can convert a nontoxic prodrug into a cytotoxic drug, thus providing targeted cell death of tumour neovasculature. Such a strategy might be expected to lead to cell death of targeted cells, plus a &#x02018;bystander&#x02019; component of neighbouring nontargeted cells killed by high concentrations of soluble drug near the targeted cells, and perhaps associated with a further bystander effect via ischaemia. Since halting angiogenesis suppresses carcinoma cell invasion (<a href="#bib37" rid="bib37" class=" bibr popnode">Skobe <em>et al</em>, 1997</a>), VEGFR-targeted CPG2 might also reduce spread of the disease. The features of the VEGF-CPG2 fusion proteins we describe here suggest that targeted therapy by LiDEPT is a feasible strategy for the targeting of activated endothelial cells in a tumour.</p><p class="p p-last">In summary, we have developed a VEGF<sub>115</sub>-CPG2(Q)3-H<sub>6</sub> fusion protein that is highly expressed, efficiently secreted, has a high specific activity, binds rapidly to its target, can direct prodrug cytotoxicity to VEGFR2-expressing cells, and is a candidate for a new approach to cancer therapy.</p></div><div id="ack-a.u.a" class="tsec sec"><h2 class="head no_bottom_margin" id="ack-a.u.atitle" style="text-transform: uppercase;">Acknowledgments</h2><div class="sec"><p>We thank Cancer Research UK for part funding this work (Grant no. SP2330&#x0002f;0201).</p></div></div><div id="ref-list-a.u.b" class="tsec sec"><h2 class="head no_bottom_margin" id="ref-list-a.u.btitle" style="text-transform: uppercase;">References</h2><div class="ref-list-sec sec" id="reference-list"><ul class="first-line-outdent"><li id="bib1"><span class="mixed-citation">Arora N, Masood R, Zheng T, Cai J, Smith DL, Gill PS (1999) <span class="ref-title">Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells</span>. <span class="ref-journal">Cancer Res</span>
<span class="ref-vol">59</span>: 183&#x02013;188 [<a href="https://pubmed.ncbi.nlm.nih.gov/9892205" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Vascular+endothelial+growth+factor+chimeric+toxin+is+highly+active+against+endothelial+cells&amp;volume=59&amp;publication_year=1999&amp;pages=183&amp;pmid=9892205&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib2"><span class="mixed-citation">Bagshawe KD (1990) <span class="ref-title">Antibody-Directed Enzyme Prodrug Therapy (ADEPT)</span>. <span class="ref-journal">Biochem Soc Trans</span>
<span class="ref-vol">18</span>: 750&#x02013;752 [<a href="https://pubmed.ncbi.nlm.nih.gov/2083666" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+Soc+Trans&amp;title=Antibody-Directed+Enzyme+Prodrug+Therapy+(ADEPT)&amp;volume=18&amp;publication_year=1990&amp;pages=750&amp;pmid=2083666&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib3"><span class="mixed-citation">Bagshawe KD, Sharma SK, Springer CJ, Antoniw P, Boden JA, Rogers GT, Burke PJ, Melton RG, Sherwood RF (1991) <span class="ref-title">Antibody Directed Enzyme Prodrug Therapy (ADEPT) &#x02013; Clinical Report</span>. <span class="ref-journal">Dis Markers</span>
<span class="ref-vol">9</span>: 233&#x02013;238 [<a href="https://pubmed.ncbi.nlm.nih.gov/1813213" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Dis+Markers&amp;title=Antibody+Directed+Enzyme+Prodrug+Therapy+(ADEPT)+&#x02013;+Clinical+Report&amp;volume=9&amp;publication_year=1991&amp;pages=233&amp;pmid=1813213&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib4"><span class="mixed-citation">Batra JK, FitzGerald DJ, Chaudhary VK, Pastan I (1991) <span class="ref-title">Single-chain immunotoxins directed at the human transferrin receptor containing pseudomonas exotoxin-A or diphtheria-toxin &#x02013; anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv)</span>. <span class="ref-journal">Mol Cell Biol</span>
<span class="ref-vol">11</span>: 2200&#x02013;2205 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC359914/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2005905" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cell+Biol&amp;title=Single-chain+immunotoxins+directed+at+the+human+transferrin+receptor+containing+pseudomonas+exotoxin-A+or+diphtheria-toxin+&#x02013;+anti-TFR(Fv)-PE40+and+DT388-anti-TFR(Fv)&amp;volume=11&amp;publication_year=1991&amp;pages=2200&amp;pmid=2005905&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib5"><span class="mixed-citation">Batra JK, Kasprzyk PG, Bird RE, Pastan I, King CR (1992) <span class="ref-title">Recombinant anti-erbB2 immunotoxins containing pseudomonas exotoxin</span>. <span class="ref-journal">Proc Natl Acad Sci</span>
<span class="ref-vol">89</span>: 5867&#x02013;5871 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC49398/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/1352878" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci&amp;title=Recombinant+anti-erbB2+immunotoxins+containing+pseudomonas+exotoxin&amp;volume=89&amp;publication_year=1992&amp;pages=5867&amp;pmid=1352878&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib6"><span class="mixed-citation">Ben Yehudah A, Yarkoni S, Nechushtan A, Belostotsky R, Lorberboum-Galski H (1999) <span class="ref-title">Linker-based GnRH-PE chimeric proteins inhibit cancer growth in nude mice</span>. <span class="ref-journal">Med Oncol</span>
<span class="ref-vol">16</span>: 38&#x02013;45 [<a href="https://pubmed.ncbi.nlm.nih.gov/10382941" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Med+Oncol&amp;title=Linker-based+GnRH-PE+chimeric+proteins+inhibit+cancer+growth+in+nude+mice&amp;volume=16&amp;publication_year=1999&amp;pages=38&amp;pmid=10382941&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib7"><span class="mixed-citation">Blaauwgeers HGT, Holtkamp GM, Rutten H, Witmer AN, Koolwijk P, Partanen TA, Alitalo K, Kroon ME, Kijlstra A, van-Hinsbergh VWM, Schlingemann RO (1999) <span class="ref-title">Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation</span>. <span class="ref-journal">Am J Pathol</span>
<span class="ref-vol">155</span>: 421&#x02013;428 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1866848/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10433935" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Pathol&amp;title=Polarized+vascular+endothelial+growth+factor+secretion+by+human+retinal+pigment+epithelium+and+localization+of+vascular+endothelial+growth+factor+receptors+on+the+inner+choriocapillaris.+Evidence+for+a+trophic+paracrine+relation&amp;volume=155&amp;publication_year=1999&amp;pages=421&amp;pmid=10433935&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib8"><span class="mixed-citation">Brinkmann U, Pai LH, FitzGerald DJ, Willingham M, Pastan I (1991) <span class="ref-title">B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice</span>. <span class="ref-journal">Proc Natl Acad Sci</span>
<span class="ref-vol">88</span>: 8616&#x02013;8620 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC52560/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/1924323" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci&amp;title=B3(Fv)-PE38KDEL,+a+single-chain+immunotoxin+that+causes+complete+regression+of+a+human+carcinoma+in+mice&amp;volume=88&amp;publication_year=1991&amp;pages=8616&amp;pmid=1924323&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib9"><span class="mixed-citation">Chaudhary VK, FitzGerald DJ, Adhya S, Pastan I (1987) <span class="ref-title">Activity of a recombinant fusion protein between transforming growth-factor type-alpha and pseudomonas toxin</span>. <span class="ref-journal">Proc Natl Acad Sci</span>
<span class="ref-vol">84</span>: 4538&#x02013;4542 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC305125/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3299371" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci&amp;title=Activity+of+a+recombinant+fusion+protein+between+transforming+growth-factor+type-alpha+and+pseudomonas+toxin&amp;volume=84&amp;publication_year=1987&amp;pages=4538&amp;pmid=3299371&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib10"><span class="mixed-citation">Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I (1989) <span class="ref-title">A recombinant immunotoxin consisting of 2 antibody variable domains fused to pseudomonas exotoxin</span>. <span class="ref-journal">Nature</span>
<span class="ref-vol">339</span>: 394&#x02013;397 [<a href="https://pubmed.ncbi.nlm.nih.gov/2498664" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=A+recombinant+immunotoxin+consisting+of+2+antibody+variable+domains+fused+to+pseudomonas+exotoxin&amp;volume=339&amp;publication_year=1989&amp;pages=394&amp;pmid=2498664&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib11"><span class="mixed-citation">Evan GI, Lewis GK, Ramsay G, Bishop JM (1985) <span class="ref-title">Isolation of monoclonal-antibodies specific for human C-MYC proto-oncogene product</span>. <span class="ref-journal">Mol Cell Biol</span>
<span class="ref-vol">5</span>: 3610&#x02013;3616 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC369192/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3915782" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cell+Biol&amp;title=Isolation+of+monoclonal-antibodies+specific+for+human+C-MYC+proto-oncogene+product&amp;volume=5&amp;publication_year=1985&amp;pages=3610&amp;pmid=3915782&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib12"><span class="mixed-citation">Fidler IJ, Ellis LM (1994) <span class="ref-title">The implications of angiogenesis for the biology and therapy of cancer metastasis</span>. <span class="ref-journal">Cell</span>
<span class="ref-vol">79</span>: 185&#x02013;188 [<a href="https://pubmed.ncbi.nlm.nih.gov/7525076" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=The+implications+of+angiogenesis+for+the+biology+and+therapy+of+cancer+metastasis&amp;volume=79&amp;publication_year=1994&amp;pages=185&amp;pmid=7525076&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib13"><span class="mixed-citation">Folkman J (1995) <span class="ref-title">Clinical applications of research in angiogenesis</span>. <span class="ref-journal">N Engl J Med</span>
<span class="ref-vol">333</span>: 1757&#x02013;1763 [<a href="https://pubmed.ncbi.nlm.nih.gov/7491141" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Clinical+applications+of+research+in+angiogenesis&amp;volume=333&amp;publication_year=1995&amp;pages=1757&amp;pmid=7491141&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib14"><span class="mixed-citation">Francisco JA, Gilliland LK, Stebbins MR, Norris NA, Ledbetter JA, Siegall CB (1995) <span class="ref-title">Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen</span>. <span class="ref-journal">Cancer Res</span>
<span class="ref-vol">55</span>: 3099&#x02013;3104 [<a href="https://pubmed.ncbi.nlm.nih.gov/7541711" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Activity+of+a+single-chain+immunotoxin+that+selectively+kills+lymphoma+and+other+B-lineage+cells+expressing+the+CD40+antigen&amp;volume=55&amp;publication_year=1995&amp;pages=3099&amp;pmid=7541711&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib15"><span class="mixed-citation">Frei E, Teicher BA, Holden SA, Cathcart KNS, Wang YY (1988) <span class="ref-title">Preclinical studies and clinical correlation of the effect of alkylating dose</span>. <span class="ref-journal">Cancer Res</span>
<span class="ref-vol">48</span>: 6417&#x02013;6423 [<a href="https://pubmed.ncbi.nlm.nih.gov/3180059" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Preclinical+studies+and+clinical+correlation+of+the+effect+of+alkylating+dose&amp;volume=48&amp;publication_year=1988&amp;pages=6417&amp;pmid=3180059&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib16"><span class="mixed-citation">Fukumura D, Xavier R, Sugiura T, Chen Y, Park E-C, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, Seed B (1998) <span class="ref-title">Tumor induction of VEGF promoter activity in stromal cells</span>. <span class="ref-journal">Cell</span>
<span class="ref-vol">94</span>: 715&#x02013;725 [<a href="https://pubmed.ncbi.nlm.nih.gov/9753319" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Tumor+induction+of+VEGF+promoter+activity+in+stromal+cells&amp;volume=94&amp;publication_year=1998&amp;pages=715&amp;pmid=9753319&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib17"><span class="mixed-citation">Gawlak SL, Pastan I, Siegall CB (1993) <span class="ref-title">Basic fibroblast growth factor-pseudomonas exotoxin chimeric proteins &#x02013; comparison with acidic fibroblast growth factor-pseudomonas exotoxin</span>. <span class="ref-journal">Bioconjug Chem</span>
<span class="ref-vol">4</span>: 483&#x02013;489 [<a href="https://pubmed.ncbi.nlm.nih.gov/7508267" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioconjug+Chem&amp;title=Basic+fibroblast+growth+factor-pseudomonas+exotoxin+chimeric+proteins+&#x02013;+comparison+with+acidic+fibroblast+growth+factor-pseudomonas+exotoxin&amp;volume=4&amp;publication_year=1993&amp;pages=483&amp;pmid=7508267&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib18"><span class="mixed-citation">Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR (1989) <span class="ref-title">Site-directed mutagenesis by overlap extension using the polymerase chain-reaction</span>. <span class="ref-journal">Gene</span>
<span class="ref-vol">77</span>: 51&#x02013;59 [<a href="https://pubmed.ncbi.nlm.nih.gov/2744487" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gene&amp;title=Site-directed+mutagenesis+by+overlap+extension+using+the+polymerase+chain-reaction&amp;volume=77&amp;publication_year=1989&amp;pages=51&amp;pmid=2744487&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib19"><span class="mixed-citation">Hogg PJ, Johnston SC, Bowles MR, Pond SM, Winzor DJ (1987) <span class="ref-title">Evaluation of equilibrium-constants for antigen&#x02013;antibody interactions by solid-phase immunoassay &#x02013; the binding of paraquat to its elicited mouse monoclonal-antibody</span>. <span class="ref-journal">Mol Immunol</span>
<span class="ref-vol">24</span>: 797&#x02013;801 [<a href="https://pubmed.ncbi.nlm.nih.gov/3657807" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Immunol&amp;title=Evaluation+of+equilibrium-constants+for+antigen&#x02013;antibody+interactions+by+solid-phase+immunoassay+&#x02013;+the+binding+of+paraquat+to+its+elicited+mouse+monoclonal-antibody&amp;volume=24&amp;publication_year=1987&amp;pages=797&amp;pmid=3657807&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib20"><span class="mixed-citation">Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW (1991) <span class="ref-title">The vascular endothelial growth-factor family &#x02013; identification of a 4th molecular-species and characterization of alternative splicing of DNA</span>. <span class="ref-journal">Mol Endocrinol</span>
<span class="ref-vol">5</span>: 1806&#x02013;1814 [<a href="https://pubmed.ncbi.nlm.nih.gov/1791831" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Endocrinol&amp;title=The+vascular+endothelial+growth-factor+family+&#x02013;+identification+of+a+4th+molecular-species+and+characterization+of+alternative+splicing+of+DNA&amp;volume=5&amp;publication_year=1991&amp;pages=1806&amp;pmid=1791831&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib21"><span class="mixed-citation">Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, Ferrara N (1996) <span class="ref-title">The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency</span>. <span class="ref-journal">J Biol Chem</span>
<span class="ref-vol">271</span>: 7788&#x02013;7795 [<a href="https://pubmed.ncbi.nlm.nih.gov/8631822" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;title=The+carboxyl-terminal+domain+(111-165)+of+vascular+endothelial+growth+factor+is+critical+for+its+mitogenic+potency&amp;volume=271&amp;publication_year=1996&amp;pages=7788&amp;pmid=8631822&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib22"><span class="mixed-citation">Kim I, Ryan AM, Rohan R, Amano S, Agular S, Miller JW, Adamis AP (1999) <span class="ref-title">Constitutive expression of VEGF, VEGF-1, and VEGFR-2 in normal eyes</span>. <span class="ref-journal">Invest Ophthalmol Vis Sci</span>
<span class="ref-vol">40</span>: 2115&#x02013;2121 [<a href="https://pubmed.ncbi.nlm.nih.gov/10440268" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Invest+Ophthalmol+Vis+Sci&amp;title=Constitutive+expression+of+VEGF,+VEGF-1,+and+VEGFR-2+in+normal+eyes&amp;volume=40&amp;publication_year=1999&amp;pages=2115&amp;pmid=10440268&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib23"><span class="mixed-citation">Kreitman RJ, Schneider WP, Queen C, Tsudo M, FitzGerald DJP, Waldmann TA, Pastan I (1992) <span class="ref-title">Mik-beta 1(Fv)-PE40, a recombinant immunotoxin cytotoxic toward cells bearing the beta-chain of the IL-2 receptor</span>. <span class="ref-journal">J Immunol</span>
<span class="ref-vol">149</span>: 2810&#x02013;2815 [<a href="https://pubmed.ncbi.nlm.nih.gov/1401913" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=Mik-beta+1(Fv)-PE40,+a+recombinant+immunotoxin+cytotoxic+toward+cells+bearing+the+beta-chain+of+the+IL-2+receptor&amp;volume=149&amp;publication_year=1992&amp;pages=2810&amp;pmid=1401913&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib24"><span class="mixed-citation">Kunwar S, Pai LH, Pastan I (1993) <span class="ref-title">Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma-multiforme cells</span>. <span class="ref-journal">J Neurosurg</span>
<span class="ref-vol">79</span>: 569&#x02013;576 [<a href="https://pubmed.ncbi.nlm.nih.gov/7692018" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurosurg&amp;title=Cytotoxicity+and+antitumor+effects+of+growth+factor-toxin+fusion+proteins+on+human+glioblastoma-multiforme+cells&amp;volume=79&amp;publication_year=1993&amp;pages=569&amp;pmid=7692018&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib25"><span class="mixed-citation">Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) <span class="ref-title">Vascular endothelial growth-factor is a secreted angiogenic mitogen</span>. <span class="ref-journal">Science</span>
<span class="ref-vol">246</span>: 1306&#x02013;1309 [<a href="https://pubmed.ncbi.nlm.nih.gov/2479986" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Vascular+endothelial+growth-factor+is+a+secreted+angiogenic+mitogen&amp;volume=246&amp;publication_year=1989&amp;pages=1306&amp;pmid=2479986&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib26"><span class="mixed-citation">Marais R, Spooner RA, Light Y, Martin J, Springer CJ (1996) <span class="ref-title">Gene-directed enzyme prodrug therapy with a mustard prodrug&#x0002f;carboxypeptidase G2 combination</span>. <span class="ref-journal">Cancer Res</span>
<span class="ref-vol">56</span>: 4735&#x02013;4742 [<a href="https://pubmed.ncbi.nlm.nih.gov/8840992" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Gene-directed+enzyme+prodrug+therapy+with+a+mustard+prodrug&#x0002f;carboxypeptidase+G2+combination&amp;volume=56&amp;publication_year=1996&amp;pages=4735&amp;pmid=8840992&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib27"><span class="mixed-citation">Marais R, Spooner RA, Stribbling SM, Light Y, Martin J, Springer CJ (1997) <span class="ref-title">A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy</span>. <span class="ref-journal">Nat Biotech</span>
<span class="ref-vol">15</span>: 1373&#x02013;1377 [<a href="https://pubmed.ncbi.nlm.nih.gov/9415889" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Biotech&amp;title=A+cell+surface+tethered+enzyme+improves+efficiency+in+gene-directed+enzyme+prodrug+therapy&amp;volume=15&amp;publication_year=1997&amp;pages=1373&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib28"><span class="mixed-citation">Martin J, Stribbling SM, Poon GK, Begent RHJ, Napier M, Sharma SK, Springer CJ (1997) <span class="ref-title">Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial</span>. <span class="ref-journal">Cancer Chemotherapy Pharmacol</span>
<span class="ref-vol">40</span>: 189&#x02013;201 [<a href="https://pubmed.ncbi.nlm.nih.gov/9219501" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Chemotherapy+Pharmacol&amp;title=Antibody-directed+enzyme+prodrug+therapy:+pharmacokinetics+and+plasma+levels+of+prodrug+and+drug+in+a+phase+I+clinical+trial&amp;volume=40&amp;publication_year=1997&amp;pages=189&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib29"><span class="mixed-citation">Mesri EA, Kreitman RJ, Fu YM, Epstein SE, Pastan I (1993) <span class="ref-title">Heparin-binding transforming growth-factor alpha-pseudomonas exotoxin-A. A heparan sulphate-modulated recombinant toxin cytotoxic to cancer- cells and proliferating smooth-muscle cells</span>. <span class="ref-journal">J Biol Chem</span>
<span class="ref-vol">268</span>: 4853&#x02013;4862 [<a href="https://pubmed.ncbi.nlm.nih.gov/8444864" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;title=Heparin-binding+transforming+growth-factor+alpha-pseudomonas+exotoxin-A.+A+heparan+sulphate-modulated+recombinant+toxin+cytotoxic+to+cancer-+cells+and+proliferating+smooth-muscle+cells&amp;volume=268&amp;publication_year=1993&amp;pages=4853&amp;pmid=8444864&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib30"><span class="mixed-citation">Napier MP, Sharma SK, Springer CJ, Bagshawe KD, Green AJ, Martin J, Stribbling SM, Cushen N, O'Malley D, Begent RH (2000) <span class="ref-title">Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma</span>. <span class="ref-journal">Clin Cancer Res</span>
<span class="ref-vol">6</span>: 765&#x02013;772 [<a href="https://pubmed.ncbi.nlm.nih.gov/10741695" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Antibody-directed+enzyme+prodrug+therapy:+efficacy+and+mechanism+of+action+in+colorectal+carcinoma&amp;volume=6&amp;publication_year=2000&amp;pages=765&amp;pmid=10741695&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib31"><span class="mixed-citation">Niculescu-Duvaz I, Niculescu-Duvaz D, Friedlos F, Spooner R, Martin J, Marais R, Springer CJ (1999) <span class="ref-title">Self-immolative anthracycline prodrugs for suicide gene therapy</span>. <span class="ref-journal">J Med Chem</span>
<span class="ref-vol">42</span>: 2485&#x02013;2489 [<a href="https://pubmed.ncbi.nlm.nih.gov/10395490" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Med+Chem&amp;title=Self-immolative+anthracycline+prodrugs+for+suicide+gene+therapy&amp;volume=42&amp;publication_year=1999&amp;pages=2485&amp;pmid=10395490&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib32"><span class="mixed-citation">Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E, Neufeld G (1997) <span class="ref-title">VEGF(145), a secreted vascular endothelial growth factor isoform that binds to extracellular matrix</span>. <span class="ref-journal">J Biol Chem</span>
<span class="ref-vol">272</span>: 7151&#x02013;7158 [<a href="https://pubmed.ncbi.nlm.nih.gov/9054410" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;title=VEGF(145),+a+secreted+vascular+endothelial+growth+factor+isoform+that+binds+to+extracellular+matrix&amp;volume=272&amp;publication_year=1997&amp;pages=7151&amp;pmid=9054410&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib33"><span class="mixed-citation">Prior TI, Helman LJ, FitzGerald DJ, Pastan I (1991) <span class="ref-title">Cytotoxic activity of a recombinant fusion protein between insulin-like growth factor-I and pseudomonas exotoxin</span>. <span class="ref-journal">Cancer Res</span>
<span class="ref-vol">51</span>: 174&#x02013;180 [<a href="https://pubmed.ncbi.nlm.nih.gov/1846308" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Cytotoxic+activity+of+a+recombinant+fusion+protein+between+insulin-like+growth+factor-I+and+pseudomonas+exotoxin&amp;volume=51&amp;publication_year=1991&amp;pages=174&amp;pmid=1846308&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib34"><span class="mixed-citation">Sharma SK, Bagshawe KD, Burke PJ, Boden JA, Rogers GT (1990) <span class="ref-title">Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model</span>. <span class="ref-journal">Br J Cancer</span>
<span class="ref-vol">61</span>: 659&#x02013;662 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1971605/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2337503" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br+J+Cancer&amp;title=Inactivation+and+clearance+of+an+anti-CEA+carboxypeptidase+G2+conjugate+in+blood+after+localisation+in+a+xenograft+model&amp;volume=61&amp;publication_year=1990&amp;pages=659&amp;pmid=2337503&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib35"><span class="mixed-citation">Sherwood RF, Melton RG, Alwan SM, Hughes P (1985) <span class="ref-title">Purification and properties of carboxypeptidase G2 from pseudomonas sp. Strain RS-16 - use of a novel triazine dye affinity method</span>. <span class="ref-journal">Eur J Biochem</span>
<span class="ref-vol">148</span>: 447&#x02013;453 [<a href="https://pubmed.ncbi.nlm.nih.gov/3838935" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+J+Biochem&amp;title=Purification+and+properties+of+carboxypeptidase+G2+from+pseudomonas+sp.+Strain+RS-16+-+use+of+a+novel+triazine+dye+affinity+method&amp;volume=148&amp;publication_year=1985&amp;pages=447&amp;pmid=3838935&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib36"><span class="mixed-citation">Siegall CB, Bacus SS, Cohen BD, Plowman GD, Mixan B, Chace D, Chin DM, Goetze A, Green JM, Hellstrom I, Hellstrom KE, Fell HP (1995) <span class="ref-title">HER4 expression correlates with cytotoxicity directed by a heregulin-toxin fusion protein</span>. <span class="ref-journal">J Biol Chem</span>
<span class="ref-vol">270</span>: 7625&#x02013;7630 [<a href="https://pubmed.ncbi.nlm.nih.gov/7535774" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;title=HER4+expression+correlates+with+cytotoxicity+directed+by+a+heregulin-toxin+fusion+protein&amp;volume=270&amp;publication_year=1995&amp;pages=7625&amp;pmid=7535774&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib37"><span class="mixed-citation">Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE (1997) <span class="ref-title">Halting angiogenesis suppresses carcinoma cell invasion</span>. <span class="ref-journal">Nat Med</span>
<span class="ref-vol">3</span>: 1222&#x02013;1227 [<a href="https://pubmed.ncbi.nlm.nih.gov/9359696" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Med&amp;title=Halting+angiogenesis+suppresses+carcinoma+cell+invasion&amp;volume=3&amp;publication_year=1997&amp;pages=1222&amp;pmid=9359696&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib38"><span class="mixed-citation">Spooner RA, Martin J, Friedlos F, Marais R, Springer CJ (2000) <span class="ref-title">In suicide gene therapy, the site of subcellular localisation of the activating enzyme is more important than the rate at which it activates prodrug</span>. <span class="ref-journal">Cancer Gene Therapy</span>
<span class="ref-vol">7</span>: 1348&#x02013;1356 [<a href="https://pubmed.ncbi.nlm.nih.gov/11059693" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Gene+Therapy&amp;title=In+suicide+gene+therapy,+the+site+of+subcellular+localisation+of+the+activating+enzyme+is+more+important+than+the+rate+at+which+it+activates+prodrug&amp;volume=7&amp;publication_year=2000&amp;pages=1348&amp;pmid=11059693&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib39"><span class="mixed-citation">Springer CJ (1993) <span class="ref-title">CMDA, an antineoplastic drug</span>. <span class="ref-journal">Drugs Future</span>
<span class="ref-vol">18</span>: 212&#x02013;215 <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Drugs+Future&amp;title=CMDA,+an+antineoplastic+drug&amp;volume=18&amp;publication_year=1993&amp;pages=212&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib40"><span class="mixed-citation">Springer CJ, Dowell R, Burke PJ, Hadley E, Davies DH, Blakey DC, Melton RG, Niculescu-Duvaz I (1995) <span class="ref-title">Optimization of alkyating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767P) for antibody-directed enzyme prodrug therapy (ADEPT)</span>. <span class="ref-journal">J Med Chem</span>
<span class="ref-vol">38</span>: 5051&#x02013;5065 [<a href="https://pubmed.ncbi.nlm.nih.gov/8544182" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Med+Chem&amp;title=Optimization+of+alkyating+agent+prodrugs+derived+from+phenol+and+aniline+mustards:+a+new+clinical+candidate+prodrug+(ZD2767P)+for+antibody-directed+enzyme+prodrug+therapy+(ADEPT)&amp;volume=38&amp;publication_year=1995&amp;pages=5051&amp;pmid=8544182&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib41"><span class="mixed-citation">Stribbling SM, Friedlos F, Martin J, Davies L, Spooner RA, Marais R, Springer CJ (2000) <span class="ref-title">Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect</span>. <span class="ref-journal">Hum Gene Ther</span>
<span class="ref-vol">11</span>: 285&#x02013;292 [<a href="https://pubmed.ncbi.nlm.nih.gov/10680842" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hum+Gene+Ther&amp;title=Regressions+of+established+breast+carcinoma+xenografts+by+carboxypeptidase+G2+suicide+gene+therapy+and+the+prodrug+CMDA+are+due+to+a+bystander+effect&amp;volume=11&amp;publication_year=2000&amp;pages=285&amp;pmid=10680842&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib42"><span class="mixed-citation">Stribbling SM, Martin J, Pedley RB, Boden JA, Sharma SK, Springer CJ (1997) <span class="ref-title">Biodistribution of an antibody-enzyme conjugate for ADEPT in nude mice bearing a human colon adenocarcinoma xenograft</span>. <span class="ref-journal">Cancer Chemotherapy Pharmacol</span>
<span class="ref-vol">40</span>: 277&#x02013;284 [<a href="https://pubmed.ncbi.nlm.nih.gov/9225945" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Chemotherapy+Pharmacol&amp;title=Biodistribution+of+an+antibody-enzyme+conjugate+for+ADEPT+in+nude+mice+bearing+a+human+colon+adenocarcinoma+xenograft&amp;volume=40&amp;publication_year=1997&amp;pages=277&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib43"><span class="mixed-citation">Teicher BA, Frei E (1988) <span class="ref-title">Development of alkylating agent-resistant human- tumor cell-lines</span>. <span class="ref-journal">Cancer Chemotherapy Pharmacol</span>
<span class="ref-vol">21</span>: 292&#x02013;298 [<a href="https://pubmed.ncbi.nlm.nih.gov/3370736" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Chemotherapy+Pharmacol&amp;title=Development+of+alkylating+agent-resistant+human-+tumor+cell-lines&amp;volume=21&amp;publication_year=1988&amp;pages=292&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib44"><span class="mixed-citation">Tischer E, Gospodarowicz D, Mitchell R, Silva M, Schilling J, Lau K, Crisp T, Fiddes JC, Abraham JA (1989) <span class="ref-title">Vascular endothelial growth-factor &#x02013; a new member of the platelet-derived growth factor gene family</span>. <span class="ref-journal">Biochem Biophys Res Commun</span>
<span class="ref-vol">165</span>: 1198&#x02013;1206 [<a href="https://pubmed.ncbi.nlm.nih.gov/2610687" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+Biophys+Res+Commun&amp;title=Vascular+endothelial+growth-factor+&#x02013;+a+new+member+of+the+platelet-derived+growth+factor+gene+family&amp;volume=165&amp;publication_year=1989&amp;pages=1198&amp;pmid=2610687&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="bib45"><span class="mixed-citation">Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) <span class="ref-title">United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in Experimental Neoplasia (second edition)</span>. <span class="ref-journal">Br J Cancer</span>
<span class="ref-vol">77</span>: 1&#x02013;10 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2151254/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9459138" ref="reftype=pubmed&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br+J+Cancer&amp;title=United+Kingdom+Co-ordinating+Committee+on+Cancer+Research+(UKCCCR)+guidelines+for+the+welfare+of+animals+in+Experimental+Neoplasia+(second+edition)&amp;volume=77&amp;publication_year=1998&amp;pages=1&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2377106&amp;issue-id=166068&amp;journal-id=334&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li></ul></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr /><div class="half_rhythm">Articles from <span class="acknowledgment-journal-title">British Journal of Cancer</span> are provided here courtesy of <strong>Cancer Research UK</strong></div><hr /></div><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC2377106/pdf/88-6600911a.pdf" class="int-view">PDF (228K)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/2377106/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/2377106/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="2377106" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2377106%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="7A2ddqVUMIutpJIxyALq6OpoporpG0hUQuMLI4SWreQszJ50BBDwvdKgIpx2MASP">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2377106%2F&amp;text=A%20novel%20vascular%20endothelial%20growth%20factor-directed%20therapy%20that%20selectively%20activates%20cytotoxic%20prodrugs" alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2377106%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377106/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC2377106/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/12771932/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC2377106/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/12771932/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC2377106/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/2377106/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.038d36e4e31104b40a19.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.228f96f3298e.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.b7dd20e527283dd68f45.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC2377106/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
